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ABSTRACT 
 
In humans, advanced malignancies are often targeted with broad- 
spectrum cytotoxic drugs that engender several detrimental side effects, in 
addition to their primary usage for eradicating cancerous cells. One of the 
lesser-researched of these effects, histological distortion of the olfactory system 
impedes a patient’s ability to smell, perceive flavor, and ultimately may 
interfere with their nutritional intake and recovery from chemotherapy. Recent 
studies have indicated that cytotoxic drugs can damage gustatory epithelia 
immediately following administration (Mukherjee & Delay, 2011, 2013). We 
sought to observe the histological effects that cyclophosphamide (CYP), one of 
the oldest and most popular alkylating antineoplastic agents, may have on the 
murine main olfactory epithelium (MOE) and vomeronasal organ (VNO). We 
utilized two immunohistochemical antibodies to label cells in the olfactory 
epithelia: anti-Ki67, a marker strictly associated with cell proliferation; and, 
anti-Keratin 5, a marker for the cytoskeleton of horizontal basal cells. Twenty-
eight C57BL/6 mice were administered a single intraperitoneal injection of 
CYP (75 mg/kg), while 20 control mice were administered saline, all at 
approximately seven weeks of age. Mice were euthanized at days one, two, six, 
14, 30, and 45 post injection; subsequently, they were perfused with 4% 
paraformaldehyde, decalcified, cryoprotected, cryosectioned, and incubated 
with anti-Ki67 and anti-Keratin 5 antibodies, sequentially. Quantification 
results by fluorescent imaging of labeled sections revealed a significant 
decrease in the number of proliferative cells in the MOE and VNO of CYP-
injected mice within the first 10 days post injection, followed by a 
compensatory period of increased cell proliferation through day 45 post 
injection, compared to saline-injected mice. Co-localization of horizontal basal 
cells and proliferative cells in the MOE and VNO of CYP-injected mice was 
significantly amplified at approximately 14 and 45 days post injection, 
respectively, compared to saline-injected mice. Our results suggest that 
administration of CYP can rapidly depress the populations of proliferative cells 
in the murine MOE and VNO; consequently, horizontal basal cells may afford 
restoration of the proliferative cell populations in the murine MOE and VNO, 
14 to 45 days post injection, respectively.  
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 CHAPTER 1: COMPREHENSIVE LITERATURE REVIEW 
 
1.1. Chemotherapy, Cancer, and Olfactory Distortions in Human Patients 
1.1.1. Chemotherapy and Cancer: An Imperfect Union 
Chemotherapy is defined as the use of chemical agents in the treatment 
or control of disease, most notably connoted as the use of drugs in the 
treatment of cancer. Cancer is recognized as the abnormal and excessive 
growth of cells originating in one region of the body, with the potential to 
metastasize to several other or all regions (Aronovitch et al., 1960; Dick & 
Phillips, 1961; Bagley et al., 1973; Moore, 1991; Colvin, 1999; Pinto et al., 2009). 
Since cancer fundamentally involves the unregulated propagation of cells, 
several chemotherapy treatments exist to extinguish proliferative cells within 
the body. Major classes of chemotherapeutics drugs – designed to directly 
inhibit cell division and function or obstruct the synthesis of deoxyribonucleic 
acid (DNA) – include alkylating agents, antimetabolites, antitumor antibiotics, 
plant alkaloids, and topoisomerase inhibitors (Cunningham et al., 1988; Colvin, 
1999; Malet-Martino et al., 1999). However, these pharmacologic agents are not 
a panacea. Though targeted treatments of specific cancer cell types have been 
developed, the majority of common chemotherapeutics are non-specific 
intracellular poisons which disturb any cell undergoing mitosis. Moreover, 
chemotherapeutics are typically administered systemically, in that they are 
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introduced into the vascular system so that they may embroil cancer at any 
anatomic location within the body. While this systemic approach to 
chemotherapy is often effective in treating widely-metastasized cancers, it also 
engenders adverse effects relating to the extermination of normally-
proliferative cells, such as cells of the bone marrow, digestive tract, and sensory 
epithelia (Bagley et al., 1973; Colvin, 1999; Ludeman, 1999). Therefore, the 
treatment of cancer is a two-fold conundrum – not only must the propagation 
of cancerous cells be thwarted, adverse effects which arise from the systemic 
use of cytotoxic drugs must also be considered. 
1.1.2. Chemosensory Alterations Resulting from Cytotoxicity 
When a patient undergoes chemotherapy to treat cancer, there are 
generally two adverse effects that are of paramount concern to clinicians, 
patients, and researchers: immunosuppression, which can compromise an ill 
patient’s capacity to mediate secondary infections, and digestive distortions, 
which can encumber a patient’s ability to digest proper nutrients and sustain 
the energy needed to recover (Dick & Phillips, 1961; Bagley et al., 1973; Colvin, 
1999; Malet-Martino et al., 1999). A lesser-researched, yet increasingly 
noteworthy, side effect involves distortions to patients’ chemosensory systems, 
namely the gustatory and olfactory systems. There are three classifications of 
chemosensory alteration that characterize this side effect: hypogeusia and 
hyposmia, or reduced sensitivity to taste and smell, respectively; parageusia 
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and parosmia, or distorted perception of taste and smell, respectively; and 
ageusia and anosmia, or expired perception of taste and smell, respectively.  A 
multitude of clinical research has demonstrated that these alterations in 
chemotherapy patients – which can persist for years after chemotherapy 
administration – can reduce food intake and quell a patient’s appetite. One 
such study by Hutton and collaborators at the University of Alberta described 
that nearly 90% of chemotherapy patients reported some level of chemosensory 
deficit, which decreased their energy consumption, increased their weight loss, 
and decreased their quality of life scores compared to patients who did not 
experience chemosensory distortion (2007). Such effects often result in 
malnutrition, a reduced quality of life, and delayed recovery from illness 
(Comeau et al., 2001; Bernhardson et al., 2007; Hutton et al., 2007; Bernhardson 
et al., 2009; Halyard, 2009). Thus, understanding how chemotherapeutic agents 
affect the chemosensory systems is increasingly imperative for improving 
patient outcomes and refining the use of chemotherapy. 
Until recently, most of the information about chemosensory alterations 
resulting from chemotherapy was established by clinical research. That 
precedent was improved upon when a pioneering 2011 study, published by 
Mukherjee and Delay, investigated the histological basis for gustatory 
alterations reported by patients undergoing chemotherapy. After injecting 
naïve mice with a cytotoxic chemotherapeutic (e.g. cyclophosphamide), 
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Mukherjee and Delay observed a significant decrease in the number of taste 
sensory cells up to two weeks after the administration of chemotherapy. They 
were the first to demonstrate that cyclophosphamide, as a cytotoxic 
chemotherapeutic, has significant and identifiable effects on the histology of 
the murine gustatory system. Accordingly, Mukherjee and Delay suggested 
that gustatory alterations experienced by chemotherapy patients likely are due, 
in part, to histological disturbances following the administration of a cytotoxic 
drug (2011). 
Given the increasing impetus to understand how chemotherapy achieves 
chemosensory alterations, and the novel results reported by Mukherjee and 
Delay, the ensuing histological study was undertaken to observe the effects 
that administration of a cytotoxic drug (e.g. cyclophosphamide) has on basal 
and proliferative cells in the murine olfactory system. 
 
1.2. Cyclophosphamide 
1.2.1. History, Synthesis, and Mechanism of Action 
Cyclophosphamide is one of the oldest and most efficacious cytotoxic 
drugs used to treat advanced malignancies. Indeed, its prevalence and clinical 
effectiveness were the primary determinants in the decision to utilize the drug in 
the succeeding study. Cyclophosphamide (CYP) is an alkylating 
chemotherapeutic, used clinically since it became the eighth cytotoxic drug 
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approved by the United States Food and Drug Administration in 1959 
(Aronovitch et al., 1960; Foye et al., 1960; Dick & Phillips, 1961; Bagley et al., 
1973; Colvin, 1999; Malet-Martino, 1999). The development of CYP was borne out 
of the First World War, during which Germany exploited sulfur mustard as an 
operative cytotoxic agent in combat. Sulfur mustard readily eliminates a chloride 
ion by intramolecular nucleophilic substitution to form a reactive cyclic 
sulfonium ion, which causes irreversible alkylation of the guanine nucleotide in 
DNA strands. Such DNA linkages result in arrested cell proliferation and 
probable apoptosis of cells that are affected (Cunningham et al., 1988; Colvin, 
1999; Pinto et al., 2009). Cleverly, the cytotoxicity of sulfur mustard was 
recognized as a powerful tool that could potentially target the unregulated 
proliferation of cells in the body, namely cancer. However, the obvious 
impediment to using sulfur mustard as a chemotherapeutic was its 
constitutively-active mechanism of action, which contraindicated the agent for 
systemic use within the body (Foye et al., 1960; Moore, 1991). Therefore, the 
resultant aim of rational drug design was to develop a pharmacologic agent with 
the cytotoxic accuracy of a mustard, but targeted selectivity for cancerous cells.  
This objective was partially accomplished with the synthesis of CYP in 
1958. Researchers intended to create a cytotoxic chemotherapeutic based on 
mustard that could be administered as a prodrug (i.e. pharmacologically-inactive 
precursor) to be converted within the body into an active form, chiefly in cancer 
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cells. To achieve this, researchers substituted the methyl group of nitrogen 
mustard with an oxazaphosphorine ring, creating the novel structure of CYP 
(Aronovitch et al. 1960; Foye et al., 1960; Dick & Phillips, 1961; Bagley et al., 
1973). When administered into the human body, CYP is primarily converted by 
the hepatic cytochrome P450 oxidase enzymes into tautomers, 4-
hydroxycyclophosphamide and aldophosphamide, by hydroxylation of the 
oxazaphosphorine ring. A significant portion of the aldophosphamide is 
oxidized to carboxycyclophosphamide, an inert metabolite, by the enzyme 
aldehyde dehydrogenase (ALDH). Conversely, the remaining aldophosphamide 
freely diffuses into cells, where it is decomposed into two remnants: 
phosphoramide mustard and acrolein (Figure 1). After crossing into cellular 
nuclei, phosphoramide mustard is reacts to remove a chloride ion to form a 
cyclic ethyleneiminium cation. This highly unstable cation is attacked by several 
nucleophiles, most notably by DNA guanine residues. This reaction with DNA 
releases the nitrogen of the alkylating agent and makes it available to react with 
an additional side chain forming a second covalent linkage with another 
nucleophile. Consequently, the mustard interferes with DNA replication by 
forming intrastrand and interstrand DNA crosslinks at the guanine N-7 position 
(Juma et al., 1979; Juma et al., 1980; Cunningham et al., 1988; Colvin, 1999; 
Ludeman, 1999; Malet-Martino et al., 1999; Pinto et al., 2009).  The most common 
outcome of these irreversible linkages is cellular apoptosis, which is effective in 
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disrupting cancer cells that are proliferating uncontrollably. Nevertheless, a 
critical downside to using CYP as a chemotherapeutic is its non-selective action 
on all proliferating cells within the body, especially those that are accessible by 
the vascular system and receive high levels of freely-diffusible aldophosphamide 
(Dick & Phillips, 1961; Bagley et al. 1973; Moore, 1991; Colvin, 1999; Malet-
Martino et al., 1999; Bernhardson et al., 2007). This non-selectivity instigates a 
multitude of adverse effects, including disturbances to the olfactory epithelium, 
which are the focus of the ensuing study.  
1.2.2. Clinical Use and Side-Effects 
Although CYP can cause exceptional damage within non-target tissues, 
its efficacy in ablating cancerous cells indicates it for use in several advanced 
malignancies. Primarily, CYP is used as the first line of treatment in leukemia, 
lymphoma, breast cancer, and ovarian cancer (Bagley et al., 1973; Juma et al., 
1979; Juma et al., 1980; Cunningham et al., 1988; Moore, 1991; Ludeman, 1999; 
Malet-Martino et al., 1999; Pinto et al., 2009). However, because of its toxicity, 
CYP is typically used for a short duration to control cancerous cell proliferation 
before being replaced with a less toxic chemotherapeutic, or alternatively, it may 
be used in a continuous low-dose as an adjuvant to less harmful 
chemotherapeutics such as epirubicin or methotrexate (Colvin, 1999; Ludeman, 
1999). 
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One advantage of utilizing CYP is that since it is a prodrug, tissues that 
prevent the production of its active metabolite, phosphoramide mustard, are 
largely spared of damage. Indeed, regions like epithelial basal cells, the liver, and 
the digestive tract that retain high levels of ALDH often do not accumulate a 
significant quantity of freely-diffusible aldophosphamide, and thus, do not 
experience cellular damage. Even so, CYP ravages proliferative cells in any 
region of the body that permits freely-diffusible aldophosphamide to be 
decomposed in substantial quantities. As such, CYP can commonly cause severe 
cases of bone marrow suppression, neutropenia, leukopenia, thrombocytopenia, 
anemia, hemorrhagic necrotic perimyocarditis, cardiac arrhythmia, pericardial 
effusion, amenorrhea, hemorrhagic cystitis, and a host of secondary cancers 
(Cunningham et al., 1988; Colvin, 1999; Ludeman, 1999; Malet-Martino et al., 
1999; Pinto et al., 2009). 
There are several studies of chief interest to the succeeding study. These 
include several clinical cases and the histological assay by Mukherjee and Delay 
which demonstrate that CYP alters chemoreception (Comeau et al., 2001; 
Bernhardson et al., 2007; Bernhardson et al., 2009; Halyard, 2009; Mukherjee & 
Delay, 2011, 2013). To further elucidate how CYP may affect a patient’s 
chemosensory anatomy, the olfactory epithelia were chosen as the biological 
system of experimentation in ensuing study. 
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1.3. Murine Olfactory System 
Since chemoreception is comprises both gustatory and olfactory inputs 
into the mammalian nervous system, it was reasonable to investigate the effects 
of CYP on the murine olfactory system following the results exhibited by 
Mukherjee and Delay in the murine gustatory system. The murine olfactory 
system is responsible for the neurological signal transduction of odorant 
molecules that bind to specific sites on olfactory receptors, namely olfactory 
sensory neurons (OSNs); these neurons, which are characterized as Golgi type I, 
retain long axons that form glutamatergic synapses with mitral cells in the 
olfactory bulb (Naessen, 1970; Schwartz Levey et al., 1991; Weiler & Farbman, 
1997). Many vertebrates, including most mammals and reptiles but not humans, 
have two distinct and segregated olfactory systems: a main olfactory system, 
which detects volatile stimuli, and an accessory olfactory system, which detects 
fluid-phase stimuli (Schwob, 2002; Vedin et al., 2009; Holbrook et al., 2011). Mice 
have four segregated regions within their peripheral olfactory system: the main 
olfactory epithelium (MOE), the vomeronasal organ (VNO), the septal organ, and 
the Grueneberg ganglion (Holbrook et al., 1995; Weiler, 2005). As the primary 
peripheral olfactory epithelia within mice, the MOE and VNO were selected as 
the two regions of interest for the succeeding study (Figure 2). 
1.3.1. Main Olfactory Epithelium (MOE) and Vomeronasal Organ (VNO) 
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 As the workhorses of the murine olfactory system, the MOE and VNO 
retain similar anatomies and functions. Both regions are pseudostratified 
columnar epithelia, that basally to apically retain: basal cells, immature and 
mature sensory neurons, and sustentacular cells, which provide physical and 
metabolic support within the epithelia (Figure 3). Additionally, the sensory 
neurons of both the MOE and VNO are bipolar, as odorant detection is 
facilitated by elongated dendrites, and cilia (MOE) and microvilli (VNO) that 
extend apically from the epithelia (Barber & Raisman, 1978; Firestein, 2001; 
Brann & Firestein, 2010). 
While fundamentally similar in light of the histological focus of this 
study, the MOE and the VNO differ in several aspects, including: odorant 
accessibility, vascularization, signaling cascades and biological purpose. The 
MOE is a large, diffusely-vascularized epithelium in the posterior murine nasal 
cavity, which covers cartilaginous turbinates that permit abundant access to 
stimuli. In contrast, the densely-vascularized epithelium of the VNO lines a 
paired bony capsule at the base of the anterior nasal cavity, which is protected 
by a vascular pump that governs access to stimuli (Calof & Chikaraishi, 1989; 
Brann & Firestein, 2014). The MOE is organized by a basal sensory zone and an 
apical sustentacular zone, while the VNO also retains marginal zones that 
encapsulate the extremities of its crescent shape (Figure 4). Sensory neurons 
within the MOE facilitate signal transduction by increases in intracellular 
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cAMP, whereas sensory neurons within the VNO transduce signals via the 
phospholipase C pathway (Matsunami & Buck, 1997; Ryba & Tirindelli, 1997). 
Lastly, the biological purposes of the MOE and VNO have been hotly debated 
for decades: in general, it is thought that while the MOE detects a myriad of 
volatile odorants, the VNO specializes in the detection of fluid-phase stimuli, 
often in direct mediation of sexual and social behaviors (Mombaerts, 2006). 
1.3.2. Basal Cells: Postnatal Neurogenesis of the Olfactory Epithelia  
 In the murine olfactory system, the paramount concern regarding CYP-
induced cytotoxicity is disruption of the postnatal proliferation of cells. Indeed, 
both the MOE and VNO undergo continual postnatal neurogenesis in the 
generation of sensory neurons (Graziadei & Monti-Graziadei, 1979; Costanzo, 
1991; Huard et al., 1998; Legrier et al., 2001; Schwob, 2002). Both regions of the 
olfactory epithelia renew cells throughout life, although neurogenesis in the 
MOE has been shown to be twice as rapid as neurogenesis in the VNO. It is 
also important to note that while postnatal neurogenesis is continuous, the rate 
of neurogenesis in both the MOE and VNO declines with age (Weiler & 
Farbman, 1997, 1998; Brann & Firestein, 2010). In the MOE, neurogenesis 
during the first postnatal year contributes predominantly to anatomical 
growth, and later transitions to the renewal of sensory neurons during the 
lifetime of an animal. In the VNO, neurogenesis in the marginal zones is 
primarily responsible for growth, while regeneration in the sensory zone is 
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responsible for the turnover of sensory neurons over time (Barber & Raisman, 
1978; Graziadei & Monti-Graziadei, 1979; Martinez-Marcos et al., 2004; Weiler 
& Banali, 2005; Brann & Firestein 2010). In an adult mouse, the lifespan of a 
sensory neuron ranges from 30 to 90 days, increasing proportionately to the age 
of the animal (Graziadei & Monti-Graziadei, 1979; Huard & Schwob, 1997). 
Two populations of basal progenitor cells appear to be the founts of 
renewal for both natural and injury-induced neurogenesis in the MOE and 
VNO: horizontal basal cells (HBCs) and globose basal cells (GBCs) (Schwartz 
Levey et al., 1991; Caggiano et al., 1994; Holbrook et al., 1995; Farbman, 1997; 
Beites et al., 2005; Leung et al., 2007; Iwai et al., 2008; Tucker et al., 2010; Jang et 
al., 2014). HBCs are mostly quiescent and line the basal lamina (e.g. layer of 
extracellular matrix secreted by epithelial cells, on which epithelia rests) of 
olfactory epithelia, appearing histologically as densely-packed rows of narrow 
cells (Holbrook et al., 1995; Carter et al., 2004; Iwai et al., 2008; Joiner et al., 
2015). GBCs, which rest apically to HBCs, have a globular appearance and 
maintain elevated rates of mitosis compared to their HBC counterparts 
(Caggiano et al., 2005; Huard & Schwob, 1995).  It is thought that both HBCs 
and GBCs proliferate by undergoing asymmetric cell division, though the 
current knowledge of their proliferative mechanisms is deficient.  
The exact differences in histology and function between these classes of 
basal cells are unclear, based on several conflicting studies. Generally, evidence 
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does suggest that GBCs bear the majority of naturally-occurring cell renewal, 
while HBCs tend to be most active in neurogenesis during discrete instances of 
injury to the epithelia (Holbrook et al., 1995; Huard & Schwob, 1995; Carter et 
al., 2004; Leung et al., 2007). What confounds this controversy even further, 
from a histological standpoint, is that no widely-accepted 
immunohistochemical marker for GBCs exists. HBCs are immunoreactive to 
cytokeratins, but observations of their populations only reveal half of the story 
of neurogenesis in the MOE and VNO (Holbrook et al., 1995; Goldstein & 
Schwob, 1996; Joiner et al., 2015). To advance the knowledge of regeneration in 
the murine olfactory system, future studies must delineate, with certainty, the 
function and fate of HBCs and GBCs during physiological and injury-induced 
neurogenesis. 
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Figure 1: Metabolism of CYP after Pharmacologic Conversion by Hepatic 
Cytochrome P450 Enzymes. CYP is converted into tautomers, 4-
hydroxycyclophosphamide and aldophosphamide. Aldophosphamide is oxidized to 
carboxycyclophosphamide by aldehyde dehydrogenase (ALDH) or decomposed in 
cells into two remnants: phosphoramide mustard and acrolein. In cellular nuclei, 
phosphoramide mustard is subject to elimination of a chloride to form a cyclic 
ethyleneiminium cation, which is attacked by several nucleophiles, including DNA 
guanine residues. The reaction with DNA releases the nitrogen of the alkylating agent 
and forms a second covalent linkage with another nucleophile. Ultimately, the 
mustard interferes with DNA replication by forming intrastrand and interstrand DNA 
crosslinks at the guanine N-7 position. 
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Figure 2: Mid-Sagittal Section of the Murine Snout. The murine olfactory 
system comprises (anterior to posterior): the Grueneberg Ganglion (GG), the 
vomeronasal organ (VNO), the main olfactory epithelium (MOE or OE), and the septal 
organ (SO), which are exposed to the nasal cavity (NC). 
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Figure 3: Cell Types of the Murine Olfactory Epithelia. The murine olfactory 
epithelia are composed of five primary cell types (basally to apically):  horizontal basal 
cells (HBC), globose basal cells (GBC), immature olfactory sensory neurons (OSNi), 
mature olfactory sensory neurons (OSNm), and sustentacular cells (Sus). (Brann & 
Firestein, 2014) 
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Figure 4: Coronal Section of the Murine Snout, with Focus on the Main Olfactory 
Epithelium (Top Left) and the Vomeronasal Organ (Bottom Left). The primary 
organs of the murine olfactory system are the Main Olfactory Epithelium (MOE) and 
the Vomeronasal Organ (VNO). The MOE is diffusely-vascularized and located in the 
posterior nasal cavity whereas the VNO is densely-vascularized and lines a paired 
bony capsule in the anterior nasal cavity. The MOE (top left) is organized by a basal 
sensory zone (purple) and an apical sustentacular zone (green), while the VNO 
(bottom left) also retains marginal zones (yellow) that encapsulate the extremities of its 
crescent shape. 
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CHAPTER 2: CO-LOCALIZATION OF BASAL AND PROLIFERATIVE 
CELLS IN THE MURINE MAIN OLFACTORY EPITHELIUM AND 
VOMERONASAL ORGAN AFTER INJURY WITH CYCLOPHOSPHAMIDE 
 
2.1. Introduction  
Chemotherapy is defined as the use of chemical agents in the treatment 
or control of disease, most notably connoted as the use of drugs in the 
treatment of cancer. Cancer is recognized as the abnormal and excessive 
growth of cells originating in one region of the body, with the potential to 
metastasize to several other or all regions (Aronovitch et al., 1960; Dick & 
Phillips, 1961; Bagley et al., 1973; Moore, 1991; Colvin, 1999; Pinto et al., 2009). 
Major classes of chemotherapeutics drugs – designed to directly inhibit cell 
division and function or obstruct the synthesis of deoxyribonucleic acid (DNA) 
– include alkylating agents, antimetabolites, antitumor antibiotics, plant 
alkaloids, and topoisomerase inhibitors (Cunningham et al., 1988; Colvin, 1999; 
Malet-Martino et al., 1999). Though targeted treatments of specific cancer cell 
types have been developed, the majority of common chemotherapeutics are 
non-specific intracellular poisons which disturb any cell undergoing mitosis. 
Moreover, chemotherapeutics are typically administered systemically, in that 
they are introduced into the vascular system so that they may embroil cancer at 
any anatomic location within the body. While this systemic approach to 
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chemotherapy is often effective in treating widely metastasized cancers, it also 
engenders adverse effects relating to the extermination of normally-
proliferative cells, such as cells of the bone marrow, digestive tract, and sensory 
epithelia (Bagley et al., 1973; Colvin, 1999; Ludeman, 1999).  
A lesser-researched side effect involves distortions to patients’ 
chemosensory systems, namely the gustatory and olfactory systems. A 
multitude of clinical research has demonstrated that chemosensory alterations 
in chemotherapy patients – which can persist for years after chemotherapy 
administration – can reduce food intake and quell a patient’s appetite. Such 
effects often result in malnutrition, a reduced quality of life, and delayed 
recovery (Comeau et al., 2001; Bernhardson et al., 2007; Hutton et al., 2007; 
Bernhardson et al., 2009; Halyard, 2009). Until recently, most of the information 
about chemosensory alterations as a result of chemotherapy was established by 
clinical research. That precedent was improved upon when a pioneering 2011 
study, published by Mukherjee & Delay, investigated the histological basis for 
gustatory alterations reported by patients undergoing chemotherapy. After 
injecting naïve mice with a cytotoxic chemotherapeutic (e.g. 
cyclophosphamide), Mukherjee & Delay observed a significant decrease in the 
number of taste sensory cells up to two weeks after the administration of 
chemotherapy. They were the first to demonstrate that cyclophosphamide, as a 
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cytotoxic chemotherapeutic, has significant and identifiable effects on the 
histology of the murine gustatory system.  
Cyclophosphamide (CYP) is an alkylating chemotherapeutic, used 
clinically as a prodrug (Aronovitch et al., 1960; Foye et al., 1960; Dick & 
Phillips, 1961; Bagley et al., 1973; Colvin, 1999; Malet-Martino, 1999). When 
administered, CYP is primarily converted by the hepatic cytochrome P450 
oxidase enzymes into tautomers, 4-hydroxycyclophosphamide and 
aldophosphamide. A remnant of aldophosphamide - phosphoramide mustard 
– is the active chemotherapeutic agent derived from CYP. After crossing into 
cellular nuclei, phosphoramide mustard reacts with DNA to form intrastrand 
and interstrand crosslinks at the guanine N-7 position (Juma et al., 1979; Juma 
et al., 1980; Cunningham et al., 1988; Colvin, 1999; Ludeman, 1999; Malet-
Martino et al., 1999; Pinto et al., 2009).  The most common outcome of these 
irreversible linkages is cellular apoptosis, which is effective in disrupting 
cancer cells that are proliferating uncontrollably. Nevertheless, a critical 
downside to using CYP as a chemotherapeutic is its non-selective action on all 
proliferating cells within the body (Dick & Phillips, 1961; Bagley et al. 1973; 
Moore, 1991; Colvin, 1999; Malet-Martino et al., 1999; Bernhardson et al., 2007). 
As such, CYP can commonly cause severe cases of bone marrow suppression, 
neutropenia, leukopenia, thrombocytopenia, anemia, hemorrhagic necrotic 
perimyocarditis, cardiac arrhythmia, pericardial effusion, amenorrhea, 
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hemorrhagic cystitis, and a host of secondary cancers (Cunningham et al., 1988; 
Colvin, 1999; Ludeman, 1999; Malet-Martino et al., 1999; Pinto et al., 2009). Of 
chief interest to the succeeding study are the effects of CYP on chemoreception 
(Comeau et al., 2001; Bernhardson et al., 2007; Bernhardson et al., 2009; 
Halyard, 2009; Mukherjee & Delay, 2011).  
Since chemoreception is involves both gustatory and olfactory inputs 
into the mammalian nervous system, it was reasonable to investigate the effects 
of CYP on the murine olfactory system following the results exhibited by 
Mukherjee & Delay in the murine gustatory system. The murine olfactory 
system is responsible for the neurological signal transduction of odorant 
molecules that bind to specific sites on olfactory receptors, namely olfactory 
sensory neurons (OSNs) (Naessen, 1970; Schwartz Levey et al., 1991; Weiler & 
Farbman, 1997). Mice have four segregated regions within their peripheral 
olfactory system: the main olfactory epithelium (MOE), the vomeronasal organ 
(VNO), the septal organ, and the Grueneberg ganglion (Holbrook et al., 1995; 
Weiler, 2005). As the primary organs of the murine olfactory system, the MOE 
and VNO retain similar anatomies and functions. Both regions are 
pseudostratified columnar epithelia, that basally to apically retain: basal cells, 
immature and mature sensory neurons, and sustentacular cells, which provide 
physical and metabolic support within the epithelia (Firestein, 2001; Brann & 
Firestein, 2010). 
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 In the murine olfactory system, the paramount concern regarding CYP-
induced cytotoxicity is disruption of the postnatal proliferation of cells. Indeed, 
both the MOE and VNO undergo continual postnatal neurogenesis in the 
generation of sensory neurons. (Graziadei & Monti-Graziadei, 1979; Costanzo, 
1991; Huard et al., 1998; Legrier et al., 2001; Schwob, 2002). Both regions of the 
olfactory epithelia renew cells throughout life, although neurogenesis in the 
MOE has been shown to be twice as rapid as neurogenesis in the VNO. It is 
also important to note that while postnatal neurogenesis is continuous, the rate 
of neurogenesis in both the MOE and VNO declines with age (Weiler & 
Farbman, 1997, 1998; Brann & Firestein, 2010). In the MOE, neurogenesis 
during the first postnatal year contributes predominantly to anatomical 
growth, and later transitions to the renewal of sensory neurons during the 
lifetime of an animal. In the VNO, neurogenesis in the marginal zones is 
primarily responsible for growth, while regeneration in the sensory zone is 
responsible for the turnover of sensory neurons over time (Barber & Raisman, 
1978; Graziadei & Monti-Graziadei, 1979; Martinez-Marcos et al., 2004; Weiler 
& Banali, 2005; Brann & Firestein 2010). In an adult mouse, the lifespan of a 
sensory neuron ranges from 30 to 90 days, increasing proportionately to the age 
of the animal (Graziadei & Monti-Graziadei, 1979; Huard & Schwob, 1997). 
Two populations of basal progenitor cells appear to be the founts of 
renewal for both natural and injury-induced neurogenesis in the MOE and 
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VNO: horizontal basal cells (HBCs) and globose basal cells (GBCs) (Schwartz 
Levey et al., 1991; Caggiano et al., 1994; Holbrook et al., 1995; Farbman, 1997; 
Beites et al., 2005; Leung et al., 2007; Iwai et al., 2008; Tucker et al., 2010; Jang et 
al., 2014). HBCs are mostly quiescent and line the basal lamina of olfactory 
epithelia, appearing histologically as densely-packed rows of narrow cells 
(Holbrook et al., 1995; Carter et al., 2004; Iwai et al., 2008; Joiner et al., 2015). 
GBCs, which rest apically to HBCs, have a globular appearance and maintain 
elevated rates of mitosis compared to their HBC counterparts (Caggiano et al., 
2005; Huard & Schwob, 1995).  It is thought that both HBCs and GBCs 
proliferate by undergoing asymmetric cell division, though the current 
knowledge of their proliferative mechanisms is deficient. The exact differences 
in histology and function between these classes of basal cells are unclear, based 
on several conflicting studies. Generally, evidence does suggest that GBCs bear 
the majority of naturally-occurring cell renewal, while HBCs tend to be most 
active in neurogenesis during isolated instances of injury to the epithelia 
(Holbrook et al., 1995; Huard & Schwob, 1995; Carter et al., 2004; Leung et al., 
2007). What confounds this controversy even further, from a histological 
standpoint, is that no widely-accepted immunohistochemical marker for GBCs 
exists. HBCs are immunoreactive to cytokeratins, but observations of their 
populations only reveal half of the story of neurogenesis in the MOE and VNO 
(Holbrook et al., 1995; Goldstein & Schwob, 1996; Joiner et al., 2015).  
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The central aim of this study was to gain insight – from a histological 
perspective – into how cytotoxic chemotherapies achieve chemosensory 
alterations. To investigate this aim, an immunohistochemical assay was 
undertaken to observe the quantitative effects that discrete administration of 
CYP has on populations of basal and proliferative cells in the murine olfactory 
system. Specifically, we sought to observe the number of proliferative cells, and 
the number of co-localizations of basal and proliferative cells, over time in the 
MOE and VNO after a single intraperitoneal injection of CYP. These objectives 
were accomplished by staining the HBCs (anti-Keratin 5) and proliferative cells 
(anti-Ki67) within the MOE and VNO over a time-course of 45 days. 
To focus our experimental aims, we tested two hypotheses. First, since 
the olfactory epithelia demonstrate continuous neurogenesis over the lifetime 
of mice, we hypothesized that a single injection of CYP would temporarily 
decrease the number of proliferative cells in the MOE and VNO, and be 
followed by a previously-undetermined period of neurogenic recovery once 
the initial insult from CYP had subsided. Second, since HBCs are thought to be 
mostly quiescent cells and would accordingly be spared by CYP (which targets 
mitotic cells, like the GBCs), we hypothesized that the number of co-
localizations of HBCs and proliferative cells would increase after a single 
injection of CYP. We predicted that the HBCs would be activated for 
proliferation to ameliorate the injury induced by CYP, and that the greatest 
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number of co-localizations would occur 20 to 40 days after the injection of CYP, 
mirroring the normal physiological turnover of sensory neurons in the murine 
olfactory system.  
 
2.2. Methods 
2.2.1. Chemical Reagents 
CYP (cyclophosphamide monohydrate, 97%) was obtained from Acros 
Organics. All water used was acquired from a Milli-Q® Ultrapure Water 
Solutions Type 1 filtration system. All dilutions of physiological solutions were 
achieved with 0.1 M phosphate buffer, unless otherwise stated. 
2.2.2. Procurement, Injection, and Euthanasia 
Forty-eight naive C57BL/6 male mice were obtained (Jackson 
Laboratories), and acclimated to institutional housing for one week. Mice were 
housed in groupings of four individuals, and had ad libitum access to water 
and Purina Mouse Chow. The colony of mice was maintained on a 12 hour 
light-dark cycle, whereby continuous light was provided from 7:00 AM until 
7:00 PM. All mice weighed between 19 and 25 grams at the start of 
experimentation. 
 At seven weeks of age, all mice were injected intraperitoneally: 28 with a 
75 milligram per kilogram dose of CYP, and 20 with an equal volume of saline. 
Mice were euthanized at days one (CYP n=6, saline n=4), two (CYP n=6, saline 
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n=4), six (CYP n=4, saline n=4), 14 (CYP n=4, saline n=4), 30 (CYP n=4, saline 
n=2), and 45 (CYP n=4, saline n=2) post injection of CYP or saline. Each mouse 
was administered Beuthanasia®-D, immediately followed by transcardial 
perfusion with 4% paraformaldehyde in 0.1 M phosphate buffer. Following 
perfusion, snouts were dissected directly anterior to the olfactory bulb, and 
placed in solution with 4% paraformaldehyde in 0.1 M phosphate buffer. 
2.2.3. Decalcification, Cryoprotection, and Cryosectioning 
 To withstand cryosectioning for immunostaining, all snouts underwent 
decalcification and cryoprotection. Following a twenty-four hour immersion in 
4% paraformaldehyde in 0.1 M phosphate buffer and injection of 7.5% gelatin 
in buffer into the nasal cavities, all snouts were treated to a 96 hour submersion 
(with solution changes every 24 hours) in 14% ethylenediaminetetraacetic acid 
(EDTA) in 0.1 M phosphate buffer to decalcify the tissue. This was followed by 
immersion in a graded sucrose series of 0.5, 1.0, 1.5, and 2.0 M sucrose, 
sequentially, to cryoprotect the tissue. Once decalcified and cryoprotected, all 
snouts were cryosectioned at -28° F into 20 micrometer thick coronal tissue 
sections using a Microm HM 505 E cryostat. Sections were placed into well 
plates of 0.1 M phosphate buffer in preparation for immunostaining. 
2.2.4. Immunostaining and Microscope Slide Mounting 
A double-labeling procedure of two primary-secondary antibody 
pairings was performed to achieve immunostaining of HBCs and proliferative 
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cells within sections that retained the MOE and VNO. Protocols for 
immunostaining free-floating sections were performed at room temperature, 
utilizing a blocking solution (5% normal goat serum, 50% 0.1 M phosphate 
buffer, 150mM NaCL, 0.3% Triton X-100) to inhibit non-specific antigen 
binding. After cryosectioning, coronal sections with intact MOE and VNO 
morphology were transferred in groupings of three to 24 well plates. Sections 
were treated to successive washes in: 0.1 M phosphate buffer (6X, 10 minutes), 
90% methanol in 3% hydrogen peroxide (1X, 30 minutes), 0.1 M phosphate 
buffer (3X, 10 minutes), and blocking solution (1X, 60 minutes). 
 In the first stage of immunostaining, sections were incubated overnight 
(12-16 hours) in a 1:200 dilution of a rabbit monoclonal Ki67 antibody 
(ThermoFisher Scientific, RM-9106-S), which is a nuclear marker for the active 
phases of cell proliferation. After washing with 0.1 M phosphate buffer (3X, 10 
minutes) and blocking solution (1X, 60 minutes), the primary stain was 
augmented for imaging by incubation (1X, 60 minutes) in a 1:1000 dilution of 
Alexa Fluor® 546.  
In preparation for the second stage of immunostaining, all sections were 
washed with 0.1 M phosphate buffer (4X, 10 minutes) and again incubated in 
blocking solution (1X, 60 minutes). Sections were then incubated overnight (12-
16 hours) in a 1:2500 dilution of a rabbit polyclonal Keratin 5 antibody 
(BioLegend, 905501), which is a cytoskeletal marker of the intermediate 
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filaments that compose HBCs. After washing, sections were treated with a 
1:1000 dilution of Alexa Fluor® 488 (1X, 60 minutes). 
Once immunostained with anti-Ki67/Alexa Fluor® 546 and anti-Keratin 
5/Alexa Fluor® 488,  all intact sections were washed in 0.1 M phosphate buffer 
and mounted onto electrically-charged microscope slides 
(Fisherbrand™ Superfrost™ Plus) and sealed with cover glass using 
Fluoromount-G® (SouthernBiotech). Slides were dried at room temperature, 
and stored in the refrigerator until viewed. 
2.2.5. Fluorescent Visualization 
 Fluorescent visualization of the immunohistochemical double-labeling 
was accomplished by imaging on a Zeiss Axioskop 2 upright microscope. All 
sections were visualized under TRITC and FITC fluorescent filters to ascertain 
both labels. Images of every organ (e.g. MOE and VNO) in each mounted 
section were captured by NIS-Elements Basic Research microscope imaging 
software through a Photometric Cool SNAP EZ camera. All images were saved 
in both Joint Photographic Experts Group (JPEG) and Tagged Image Format 
(TIFF) file formats. 
2.2.6. Quantification  
Quantification of the double-labeling captured by fluorescent imaging 
was achieved in two parts: enumerating the number of Ki67-positive cells in 
each organ imaged, and enumerating the number of co-localizations of Keratin 
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5-positive and Ki67-positive cells in each organ imaged. At least three coronal 
sections from each mouse (CYP-injected n=28, saline-injected n=20) were 
quantified. 
During the first stage of quantification, NIS-Elements was used to 
measure the area in square micrometers of each zone within every organ (e.g. 
sensory and sustentacular zones within the MOE, and sensory, sustentacular, 
and marginal zones within the VNO). The sensory and sustentacular zones of 
the MOE and VNO were demarcated by obvious morphological distinctions. 
The marginal zones of the VNO were demarcated from zero to 30 degrees on a 
linear axis between the two crescent extremities of the VNO. Additionally, each 
cell visibly expressing anti-Ki67 in TRITC filter images was recorded. 
Altogether, a comprehensive inventory of the numerical areas of each zone and 
the number of Ki67-positive cells in each zone was completed within this stage. 
During the second stage of quantification, Adobe Photoshop was used 
to visualize the co-localization of the Keratin 5 and Ki67 double-labeling, 
presumably between HBCs and proliferative cells. Morphologically-identical 
images of each organ under TRITC and FITC fluorescent filters were imported 
into Photoshop. These images were layered, uniformly lightened so that the 
labeling captured by each filter could be viewed, and uniformly sharpened so 
that morphological distinctions were enhanced. There was no selective editing 
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of any images. Co-localization was determined by evident double-labeling at 
identical locations within each organ.  
Lastly, to account for variation in anatomy among the entire data set, the 
final quantifications were recorded as: the number of Ki67-positive cells in each 
zone by square micrometer; and the number of co-localizations of Keratin 5-
positive cells and Ki67-positive cells in each zone by square micrometer.  
2.2.7. Statistical Analyses 
 Testing for statistical significance was accomplished by subjecting each 
time-course of days post injection to a univariate analysis of variance, Levene’s 
Test for equality of variances, and a two sample t-test for equality of means 
using SPSS software (IBM Analytics). The factors utilized for statistical testing 
were treatment by day (e.g. CYP-injected versus saline-injected over one, two, 
six, 14, 30, and 45 days post injection). The univariate analyses of variance 
tested the difference in variances in the number of Ki67-positive cells and the 
number of co-localizations of Keratin 5-positive and Ki67-positive cells 
between CYP-injected mice and saline-injected mice across the total 45 days of 
experimentation following the injection procedures. Levene’s Test for equality 
of variances tested the difference in variances in the number of Ki67-positive 
cells and the number of co-localizations of Keratin 5-positive and Ki67-positive 
cells between CYP-injected mice and saline-injected mice at each day post 
injection that was studied (e.g. days one, two, six, 14, 30, and 45 post injection). 
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Finally, two-sample t-tests were performed to determine if the mean number of 
Ki67-positive cells and the mean number of co-localizations of Keratin 5-
positive and Ki67-positive cells in the olfactory epithelia of CYP-injected and 
saline-injected mice were equal at days one, two, six, 14, 30 and 45 post 
injection.  
Time-courses were established by calculating the mean number of Ki67-
positive cells or the mean number of co-localizations of Keratin 5-positive cells 
and Ki67-positive cells for both treatments every day post injection within each 
zone (e.g. MOE sensory, MOE sustentacular, VNO sensory, VNO sustentacular, 
and VNO marginal). Standard error of the mean for both treatments each day 
post injection was calculated. P-values less than alpha level 0.050 were 
considered evidence that the null hypothesis was rejected, and the differences 
between CYP-injected mice and saline-injected mice were significant. For 
statistics, N equals the number of mice that were injected and n equals the 
number of coronal sections that were quantified. As a reminder, the data set 
encompassed 28 CYP-injected mice and 20 saline-injected mice, including: days 
one (CYP N=6, saline N=4), two (CYP N=6, saline N=4), six (CYP N=4, saline 
N=4), 14 (CYP N=4, saline N=4), 30 (CYP N=4, saline N=2), and 45 (CYP N=4, 
saline N=2) post injection. A total of ten time-courses were tested, considering 
there were two parameters (e.g. number of Ki67-positive cells  and number of 
co-localizations of Keratin 5-positive cells and Ki67-positive cells) for each of 
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the five zones (e.g. MOE sensory, MOE sustentacular, VNO sensory, VNO 
sustentacular, VNO marginal) across 45 days. 
2.3. Results 
Sensory neurons in the murine MOE and the VNO are continually 
replaced during of the lifetime of mice. Therefore, they are subject to damage 
from any substance that affects their turnover as well as any environmental 
factors (such as smoking, etc.). Our study focused on insults to the MOE and 
VNO induced by CYP, after being delivered into the olfactory epithelia by the 
vascular system. Since CYP targets cells undergoing mitosis, we characterized 
CYP-induced injury in the olfactory epithelia by quantifying the number of 
proliferative cells over time after injection. Additionally, since the basal cells of 
the olfactory epithelia are thought to give rise to proliferative cells, we 
examined the number of co-localizations between HBCs and proliferative cells 
to determine the effects of CYP on impending neurogenesis in the olfactory 
epithelia. We investigated both of these parameters in five regions of the 
olfactory epithelia: MOE sensory zone, MOE sustentacular zone, VNO sensory 
zone, VNO sustentacular zone, and VNO marginal zones.  To give an accurate 
depiction of the events in each organ, the following results are divided by the 
organs of interest – the MOE and the VNO. 
For our purposes, Ki67-positive cells were indicative of olfactory cells in 
the active stages of proliferation, while Keratin 5-positive cells were indicative 
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of the HBCs. As previously mentioned, there is no verified marker for the 
GBCs in the olfactory system, so only the HBCs and proliferative cells were 
considered. Our analyses reflect the differences between CYP-injected mice and 
saline-injected mice at each day post injection that was studied. 
2.3.1. Main Olfactory Epithelium (MOE) 
Over the course of 45 days post injection, we observed the number of 
Ki67-positive cells and the number of co-localizations of Keratin 5-positive cells 
and Ki67-positive cells in the murine MOE. Analyses of both parameters were 
performed on the sensory zone and sustentacular zone. 
Ki67-positive cells were found in the sensory zone and sustentacular 
zone of the MOE at each day post injection. Both CYP-injected and saline-
injected mice revealed Ki67-positive labeling, though the extent of labeling 
differed between treatments. Ki67-positive cells were scattered in both regions 
of the MOE (Figure 5). At day zero post injection, the number of Ki67-positive 
cells in the MOE was comparable between treatments in both zones. However, 
by days two through six post injection, the number of Ki67-positive cells in 
both zones of the MOE decreased in CYP-injected mice compared to saline-
injected mice; the number of labeled cells in CYP-injected mice was 
approximately half the number of labeled cells in saline-injected mice. 
Interestingly, the number of Ki67-positive cells in saline-injected mice spiked at 
days two and six post injection. By days 14 and 30 post injection, the number of 
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Ki67-positive cells in both zones of the MOE in CYP-injected mice was elevated 
compared to saline-injected mice; there were roughly 1.5 times as a many 
labeled cells in CYP-injected mice compared to saline-injected mice (Figure 6). 
Finally, at day 45 post injection, the number of Ki67-positive cells in both zones 
of the MOE was comparable between treatments (Figures 7-9). In summary, 
CYP-injected mice experienced a transient depression in the number of labeled 
cells in the MOE within the first 14 days post injection, and then experienced an 
increase in the number of labeled cells after day 14 post injection, compared to 
saline-injected mice. The difference in Ki67-positive cells between CYP-injected 
and saline-injected mice in both zones was statistically significant at days two, 
14, and 30 post injection.  
Co-localization of Keratin 5-positive cells and Ki67-positive cells was 
only observed in the sensory zone of the MOE. Keratin 5-positive cells 
appeared oval in shape and remained congregated in large populations along 
the basal lamina of the MOE. Keratin 5-positive cells always remained adjacent 
to the basal lamina, in both CYP-injected and saline-injected mice; therefore, no 
Keratin 5 labeling appeared in the apically-located sustentacular zone (Figure 
5). At days zero, one, and two post injection, the number of co-localizations 
was comparable between treatments (Figure 5). However, by day six post 
injection, the number of co-localizations in CYP-injected mice was less than the 
number in saline-injected mice. Oppositely, by days 14 and 30 post injection, 
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the number of co-localizations in CYP-injected mice was elevated compared to 
saline-injected mice; co-localizations in CYP-injected mice were nearly double 
the number in saline-injected mice (Figure 6). Finally, by day 45 post injection, 
the number of co-localizations was comparable between treatments (Figure 7 
and 10). In summary, CYP-injected mice experienced a decrease in co-
localizations at day six post injection, but an increase in co-localizations at days 
14 and 30 post injection, compared to saline-injected mice. 
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Figure 5: Effects of CYP on Keratin 5-Positive Cells and Ki67-Positive Cells One Day Post 
Injection in the MOE, Compared to Saline Controls. Ki67-positive cells (top left) appeared  
scattered in the sensory and sustentacular zones, though they congregated in high numbers 
along the basal lamina. Keratin-5 positive cells (top right) appeared as a thin layer of cells along 
the basal lamina. Before day two post injection, CYP-injected mice (bottom right) retained a 
similar number of Ki67-positive cells (red) compared to saline-injected mice (bottom left). Also, 
the number of co-localizations between Keratin 5-positive cells (green) and Ki67-positive cells 
along the basal lamina appeared similar between CYP-injected and saline-injected mice. 
Ki67-
Positive 
Cells 
Keratin 5-
Positive 
Cells 
SALINE 
SALINE CYP 
SALINE 
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Figure 6: Effects of CYP on Keratin 5-Positive Cells and Ki67-Positive Cells in the MOE 30 
Days Post Injection, Compared to Saline Controls. By 30 days post injection, CYP-injected 
mice (bottom) retained a significantly higher number of Ki67-postive cells (red) than did saline-
injected mice (top). In CYP-injected mice, high rates of proliferation were viewed in the sensory 
zone and the sustentacular zone. Also, CYP-injected mice retained an increased number of co-
localizations between Keratin 5-positive cells (green) and Ki67-positive cells along the basal 
lamina. 
CYP 
SALINE 
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Figure 7: Effects of CYP on Keratin 5-Positive Cells and Ki67-Positive Cells in the MOE 45 
Days Post Injection, Compared to Saline Controls. By 45 days post injection, CYP-injected 
mice (bottom) retained similar numbers of Ki67-positive cells (red) in both the sensory and 
sustentacular zones compared to saline-injected mice (top). Also, the number of co-localizations 
between Keratin 5-positive cells (green) and Ki67-positive cells along the basal lamina was 
comparable between CYP-injected mice and saline-injected mice. 
CYP 
SALINE 
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Figure 8: Mean (+/- SEM) Number of Ki67-Positive Cells in the Main Olfactory 
Epithelium Sensory Zone over Days Post Injection. Compared to saline-injected mice (N=20, 
n=48), the number of Ki67-positive cells in CYP-injected mice (N=28, n=93) decreased during 
the first 10 days post injection and then increased beginning at 14 days post injection. At 45 
days post injection, there appeared to be a leveling between CYP-injected and saline-injected 
mice. The difference between CYP-injected and saline-injected mice was significant at days 
two, 14, and 30 post injection (* indicates P<0.050).  
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Figure 9: Mean (+/- SEM) Number of Ki67-Positive Cells in the Main Olfactory 
Epithelium Sustentacular Zone over Days Post Injection. Compared to saline-injected mice 
(N=20, n=48), the number of Ki67-positive cells in CYP-injected mice (N=28, n=93) decreased 
during the first 10 days post injection and then increased beginning at 14 days post injection. At 
45 days post injection, there appeared to be a leveling between CYP-injected and saline-injected 
mice. The difference between CYP-injected and saline-injected mice was significant at days 
two, 14, and 30 post injection (* indicates P<0.050).  
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Figure 10: Mean (+/- SEM) Number of Co-Localizations of Keratin 5-Positive and 
Ki67-Positive Cells in the Main Olfactory Epithelium Sensory Zone over Days Post 
Injection. The number of co-localizations in CYP-injected mice (N=28, n=93) appeared to peak 
at roughly 14 days post injection, and remained elevated compared to saline-injected mice 
(N=20, n=48) until 45 days post injection, when there was a leveling between treatments. The 
difference between CYP-injected and saline-injected mice was significant at days six, 14, and 30 
post injection (* indicates P<0.050).  
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2.3.2. Vomeronasal Organ (VNO) 
Over the course of 45 days post injection, we observed the number of 
Ki67-positive cells and the number of co-localizations of Keratin 5-positive cells 
and Ki67-positive cells in the murine VNO. Analysis of both parameters was 
performed on the sensory zone, sustentacular zone, and marginal zones. 
Ki67-positive cells were found in the sensory zone, sustentacular zone, 
and marginal zones of the VNO at each day post injection; both CYP-injected 
and saline-injected mice revealed Ki67-positive labeling, though the extent of 
labeling differed between treatments. Ki67-positive cells appeared scattered in 
all three regions of MOE, though there appeared to be a greater concentration 
of cells in the marginal zones compared to the other two regions, across time 
(Figure 11). At day zero post injection, the number of Ki67-positive cells was 
comparable between treatments in each of the three zones. However, by days 
one and two post injection, the number of Ki67-positive cells decreased in all 
three zones of CYP-injected mice, compared to saline-injected; there were 
approximately half the number of labeled cells in CYP-injected mice that there 
were in saline-injected mice (Figure 11). By day six post injection, the number 
of Ki67-positive cells in CYP-injected mice remained decreased in the sensory 
and sustentacular zones, yet the number of Ki67-positive cells in the marginal 
zones was comparable with saline-injected mice. By day 14 post-injection, the 
number of Ki67-positive cells in the sensory and sustentacular zones of CYP-
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injected mice was comparable to saline-injected mice; however, the number of 
labeled cells in the marginal zones of CYP-injected mice was extremely 
elevated – more than double - compared to saline-injected mice. By days 30 and 
45 post injection, the number of Ki67-positive cells in CYP-injected mice 
increased in all three zones compared to saline-injected mice (Figure 12). The 
peak number of Ki67-positive cells in CYP-injected mice was at day 45 post 
injection in both the sensory and sustentacular zones (Figures 12-15). In 
summary, CYP-injected mice experienced a decrease in the number of Ki67-
positive cells within the first ten days post injection, followed by a increase in 
the number of Ki67-positive cells after day 14 post injection, compared to 
saline-injected mice. This trend holds true for all three zones of the VNO, 
though the marginal zones appeared to experience the trend at a more rapid 
pace than the sensory and sustentacular zones. In the VNO sensory zone, the 
difference between CYP-injected and saline-injected mice was significant at 
days two, six, 30, and 45 post injection; in the VNO sustentacular zone, the 
difference between CYP-injected and saline-injected mice was significant at 
days one, six, 30, and 45 post injection. Similarly, in the VNO marginal zones, 
the difference between CYP-injected and saline-injected mice was significant at 
days two, 14, and 45 post injection.  
Co-localization of Keratin 5-positive cells and Ki67-positive cells was 
observed in the sensory zone and the marginal zones of the VNO. Keratin 5-
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positive cells appeared oval in shape and remained congregated in large 
populations along the basal lamina of the VNO. Keratin 5-positive cells always 
remained adjacent to the basal lamina, in both CYP-injected and saline-injected 
mice; as expected, no Keratin 5 labeling appeared in the apically-located 
sustentacular zone (Figure 11). At day zero post injection, the number of co-
localizations in the sensory zone and marginal zones was comparable between 
treatments. However, by days one and two post injection, the number of co-
localizations in both zones of CYP-injected mice was lower than the number in 
saline-injected mice (Figure 11). By day six post injection, the number of co-
localizations in the marginal zones of CYP-injected mice remained decreased, 
while the number in the sensory zone of CYP-injected mice was comparable to 
saline-injected mice. By days 14, 30, and 45 post injection, the number of co-
localizations in both zones of CYP-injected mice was elevated compared to 
saline-injected mice (Figures 12, 16-17).  For instance, by day 45 post injection, 
the number of co-localizations in the sensory zone of CYP-injected mice was 
quadruple the number in saline-injected mice. In summary, CYP-injected mice 
experienced a decrease in the number of co-localizations in both zones within 
the first six days post injection, followed by an increase in the number of co-
localizations from day 14 post injection through day 45 post  
injection, compared to saline-injected mice. While this trend held true for both 
the sensory zone and the marginal zones of the VNO, the number of co-
  
49 
localizations in the sensory zone of CYP-injected mice appeared to be 
inordinately elevated, compared to a more moderate elevation in the marginal 
zones. In the VNO sensory zone, the difference in the number of co-
localizations between CYP-injected and saline-injected mice was significant at 
day 45 post injection. In the VNO marginal zones, the difference in the number 
of co-localizations between CYP-injected and saline-injected mice was 
significant at days one and 45 post injection.  
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Figure 11: Effects of CYP on Keratin 5-Positive Cells and Ki67-Positive Cells in the VNO 
One Day Post Injection, Compared to Saline Controls. Ki67-positive cells (red) appeared 
scattered throughout the sensory, sustentacular, and marginal zones, while Keratin 5-positive 
cells (green) were congregated along the basal lamina of the sensory and marginal zones. By 
day one post injection, the number of Ki67-positive cells in CYP-injected mice (bottom) was 
decreased compared to the number in saline-injected mice (top). Also, the number of co-
localizations along the basal lamina of the sensory and marginal zones in CYP-injected mice 
was decreased compared to the number in saline-injected mice. 
SALINE 
CYP 
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Figure 12: Effects of CYP on Keratin 5-Positive Cells and Ki67-Positive Cells in the VNO 45 
Days Post Injection, Compared to Saline Controls. By 45 days post injection, the number of 
Ki67-postive cells (red) in the sensory zone, sustentacular zone, and marginal zones of CYP-
injected mice (bottom) was higher than the number in all three zones of saline-injected mice 
(top). Also, the number of co-localizations between Keratin 5-positive cells (green) and Ki67-
positive cells was higher in the sensory zone and marginal zones of CYP-injected mice than in 
either zone of saline-injected mice. 
 
SALINE 
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Figure 13: Mean (+/- SEM) Number of Ki67-Positive Cells in the Vomeronasal Organ 
Sensory Zone over Days Post Injection. Compared to saline-injected mice (N=20, n=51), the 
number of Ki67-positive cells in CYP-injected mice (N= 28, n=60) decreased during the first 14 
days post injection and then increased through 45 days post injection. The peak number of 
Ki67-positive cells in CYP-injected mice was observed 45 days post injection. The difference 
between CYP-injected and saline-injected mice was significant at days two, six, 30, and 45 post 
injection (* indicates P<0.050).  
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Figure 14: Mean (+/- SEM) Number of Ki67-Positive Cells in the Vomeronasal Organ 
Sustentacular Zone over Days Post Injection. Compared to saline-injected mice (N=20, n=51), 
the number of Ki67-positive cells in CYP-injected mice (N=28, n=60) decreased during the first 
14 days post injection and then increased through 45 days post injection. The peak number of 
Ki67-positive cells in CYP-injected mice was observed 45 days post injection. The difference 
between CYP-injected and saline-injected mice was significant at days one, six, 30, and 45 post 
injection (* indicates P<0.050).  
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Figure 15: Mean (+/- SEM) Number of Ki67-Positive Cells in the Vomeronasal Organ 
Marginal Zones over Days Post Injection. Compared to saline-injected mice (N=20, n=51), the 
number of Ki67-positive cells in CYP-injected mice (N=28, n=60) decreased during the first six 
days post injection and then increased through 45 days post injection. No leveling of the 
number of Ki67-positive cells between treatments was observed. The difference between CYP-
injected and saline-injected mice was significant at days two, 14, and 45 post injection (* 
indicates P<0.050).  
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Figure 16: Mean (+/- SEM) Number of Co-Localizations of Keratin 5-Positive and 
Ki67-Positive Cells in the Vomeronasal Organ Sensory Zone over Days Post Injection. 
Compared to saline-injected mice (N=20, n=41), the number of co-localizations in CYP-injected 
mice (N= 28, n=49) decreased until six days post injection, when the number increased through 
45 days post injection. An extreme elevation in CYP-injected mice was observed 45 days post 
injection; the difference between CYP-injected and saline-injected mice was significant by day 
45 post injection (* indicates P<0.050).  
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Figure 17: Mean (+/- SEM) Number of Co-Localizations of Keratin 5-Positive and 
Ki67-Positive Cells in the Vomeronasal Organ Marginal Zones over Days Post Injection 
Compared to saline-injected mice (N= 20, n=41), the number of co-localizations in CYP-injected 
mice (N= 28, n=49) decreased during the first ten days post injection and then increased 
through 45 days post injection. The difference between CYP-injected and saline-injected mice 
was significant at days one and 45 post injection (* indicates P<0.050).  
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2.4. Discussion 
Previous clinical research has demonstrated that administration of CYP, 
a non-specific cytotoxic drug used extensively in the treatment of cancer, can 
negatively alter chemosensory perception (Comeau et al., 2001; Bernhardson et 
al., 2007; Hutton et al., 2007; Bernhardson et al., 2009; Halyard, 2009). In 
addition to clinical outcomes, histological studies completed by Mukherjee & 
Delay have illuminated that injection of CYP can decrease the number of cells 
in the gustatory system within the first two weeks following administration 
(2011, 2013). To gain additional insight into how cytotoxic chemotherapies 
achieve chemosensory alterations, we performed an immunohistochemical 
assay to observe the quantitative effects that discrete administration of CYP has 
on populations of basal and proliferative cells in the murine olfactory system. 
We sought to enumerate the number of proliferative cells and the number of 
co-localizations of basal and proliferative cells in the MOE and VNO after a 
single intraperitoneal injection of CYP. To achieve this, we immunostained the 
HBCs (anti-Keratin 5) and proliferative cells (anti-Ki67) within the MOE and 
VNO over a time-course of 45 days.  
To focus our investigation, we formulated two hypotheses. First, since 
the olfactory epithelia demonstrate continuous neurogenesis over the lifetime 
of mice, we hypothesized that a single injection of CYP would decrease the 
number of proliferative cells in the MOE and VNO, and be followed by a 
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previously-undetermined period of neurogenic recovery once the initial insult 
from CYP had subsided. Second, since HBCs are thought to be mostly 
quiescent cells and would accordingly be spared by CYP (which targets mitotic 
cells, like the GBCs), we hypothesized that the number of co-localizations of 
HBCs and proliferative cells would increase after a single injection of CYP. We 
predicted that the HBCs would be activated for proliferation to ameliorate the 
injury induced by CYP, and that the greatest number of co-localizations would 
occur 20 to 40 days after the injection of CYP, mirroring the normal 
physiological turnover of sensory neurons in the murine olfactory system. 
Quantification results by fluorescent imaging of labeled sections 
revealed a significant decrease in the number of proliferative cells in the MOE 
and VNO of CYP-injected mice within the first 10 days post injection, followed 
by a compensatory period of increased cell proliferation through day 45 post 
injection, compared to saline-injected mice. Co-localization of HBCs and 
proliferative cells in the MOE and VNO of CYP-injected mice was significantly 
amplified at approximately 14 and 45 days post injection, respectively, 
compared to saline-injected mice. 
2.4.1. Ki67-Positive Cells  
The immunohistochemical results from the MOE and VNO demonstrate 
support for our hypothesis regarding the number of Ki67-positive cells in the 
olfactory epithelia after injection of CYP. In all five histological regions of the 
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murine olfactory system that were tested (MOE sensory zone, MOE 
sustentacular zone, VNO sensory zone, VNO sustentacular zone, and VNO 
marginal zones), administration of CYP decreased the number of Ki67-positive 
cells within the first 14 days following injection (Figures 8-9, 11, 13-15). This 
result is consistent with our current knowledge of CYP, whereby systemic 
administration of the drug targets proliferating cells within the body non-
specifically (Dick & Phillips, 1961; Bagley et al. 1973; Moore, 1991; Colvin, 1999; 
Malet-Martino et al., 1999; Bernhardson et al., 2007). It also mirrors results 
reported by Mukherjee & Delay that exhibited a depression of gustatory cells 
within the first two weeks following CYP injection (2011, 2013). 
 It is probable that CYP injected into our experimental mice reached both 
the MOE and VNO by way of the vascular system, and diminished the 
populations of Ki67-positive cells by arresting cellular proliferation. Although 
the VNO is more highly vascularized than the MOE, we observed that an 
intraperitoneal injection of CYP disrupted the number of Ki67-positive cells 
similarly in both organs. Furthermore, because administration of CYP to our 
experimental mice was limited to one injection of a single dose, we observed a 
period of recovery in the number of Ki67-positive cells 14 to 45 days after 
administration of CYP (Figures 7-9, 12-15). This finding is consistent with 
current knowledge that the murine olfactory epithelia undergo continuous 
neurogenesis over the lifetime of animals, and would be able to resume 
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proliferation after the effects of CYP subsided (Graziadei & Monti-Graziadei, 
1979; Costanzo, 1991; Weiler & Farbman, 1997, 1998; Huard et al., 1998; Legrier 
et al., 2001; Schwob, 2002; Brann & Firestein, 2010). All five regions of the 
olfactory epithelia in CYP-injected mice demonstrated a shift from decreased 
proliferation to increased proliferation compared to saline-injected mice at 
approximately 10 to 14 days post injection, compared to saline-injected mice 
(Figures 8-9, 13-15). This result suggests that a single injection of CYP induces a 
two week lag in cellular proliferation before the olfactory epithelia can resume 
normal neuronal turnover and replace cells lost to the injury. 
These results prompted several questions for consideration. First, it is 
pertinent to consider why administration of CYP did not completely decimate 
the populations of proliferative cells in either the MOE or VNO. In our 
experiment, one possible explanation is that robust proliferation in the 
olfactory epithelia of the young animals tested mitigated the cytotoxicity of the 
CYP that was administered. At seven weeks of age, C57BL/6 mice are not 
physically mature, as they continue to grow in size up to 50 weeks old (Weiler 
& Farbman, 1997, 1998; Weiler, 2005). Considering the young postnatal age of 
our mice, it is likely that at the time of injection both the MOE and the VNO 
were undergoing neurogenesis for both anatomical expansion and neuronal 
turnover. It is conceivable that the single dose of CYP administered to our mice 
was merely insufficient for complete obliteration of the Ki67-positive cells in 
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our young animals. Indeed, the idea of robust proliferation in young mice is 
evidenced by the fact that, in our study, both zones of the MOE recovered to 
normal levels of proliferation by day 45 post injection, compared to saline-
injected mice. This rapid recovery was likely facilitated by the vigorous 
proliferation occurring in our young animals prior to and after injection of 
CYP. Also, the slightly faster rates of recovery viewed in the MOE and the 
VNO marginal zones (compared to the VNO sensory and sustentacular zones) 
can likely be attributed to the fact that these regions undergo anatomical 
growth up to a year after birth, suggesting that proliferation would have been 
robust in these regions prior to injection of CYP.  
Second, since the MOE and VNO both were injured by CYP and 
experienced a subsequent period of recovered proliferation, it is pertinent to 
consider why the number of Ki67-positive cells in the MOE returned to 
comparable levels with saline-injected mice, while the number of Ki67-positive 
cells in the VNO remained significantly elevated at day 45 post injection. There 
may be several explanations for this discrepancy, though we presume it is 
likely due to asynchronous cycles of neurogenesis in the MOE and VNO. 
Neurogenesis in the MOE has been shown to be twice as rapid as neurogenesis 
in the VNO, and it is likely that our results are a snapshot of the asynchronous 
neuronal turnover in the MOE and VNO, once our animals began to recover 
from the initial insult from CYP (Graziadei & Monti-Graziadei, 1979; Costanzo,  
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1991; Huard et al., 1998; Legrier et al., 2001; Schwob, 2002). We suggest that the 
turnover of sensory neurons in the MOE and VNO may be cyclical; future 
studies should elongate the experimental time-course to clarify the rates of 
neuronal turnover across time, and examine differences in the rate of 
neurogenesis between the MOE and VNO. 
Third, it is necessary to consider why our results showed a spike in the 
number of Ki67-positive cells in saline-injected mice (particularly in the MOE) 
at days two and six post injection, especially since we observed a decrease in 
the number of Ki67-positive cells in CYP-injected mice at the same time points 
(Figures 8-9, 13-15). It is important to note that there was absolutely no cross-
contamination of CYP and saline during the injection procedures, as CYP and 
saline injections were administered in different fume hoods with similar 
accommodations within the same building. Without cross-contamination, an 
odorant fear response does not explain the spike in Ki67-positive cells we 
observed in the saline-injected mice. However, our experimental mice were 
both naïve and young, having never been handled until the day of their 
injection. Therefore, it is plausible that the spike in Ki67-positive cells in saline-
injected mice at days two and six post injection resulted from an acute stress 
response precipitated by the injection procedures (Morton et al., 2001). In fact, 
intraperitoneal injection has been found to cause the highest levels of acute 
stress of any injection procedure used on mice (Meijer et al., 2006).  
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Fourth, it is interesting to consider the remarkably high levels of 
proliferation viewed in the VNO sustentacular zone by 30 days post injection 
and beyond (Figures 12, 14). Since the VNO sustentacular zone is apical to the 
VNO sensory zone, there was no previous indication that a significant 
population of stem cells existed within the VNO sustentacular zone. 
Conventional knowledge suggested that the sensory zone retained a swathe of 
HBCs along the basal lamina as well as a population of GBCs that give rise to 
neuronal cell bodies located within the sensory zone (Caggiano et al., 2005; 
Huard & Schwob, 1995). In this paradigm, we would expect the high levels of 
post-injury proliferation we see in the VNO sensory zone, but not such high 
levels in the VNO sustentacular zone. Since our results demonstrate three times 
the amount of proliferation in the VNO sustentacular zone in CYP-injected 
mice compared to saline-injected mice, we hypothesize that the VNO 
sustentacular zone may retain a more significant population of stem cells than 
previously considered.  
Overall, our results suggest that a single intraperitoneal injection of CYP 
significantly depresses the number of proliferative cells in the MOE and VNO, 
and instigates a subsequent period of neurogenic recovery governed by 
continual neurogenesis. In the olfactory epithelia of young mice like those we 
tested, we suggest that the depressive effects of CYP should be viewed within 
the first 14 days post injection. If only one dose of CYP is administered, we 
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suggest that proliferation within the olfactory epithelia should begin to recover 
approximately two weeks after injection, though the rates of recovery may 
differ between the MOE and the VNO. 
2.4.2. Co-Localization of Keratin 5-Positive Cells and Ki67-Positive Cells  
The immunohistochemical results from the MOE and VNO demonstrate 
support for our hypothesis regarding the number of co-localizations of Keratin 
5-positive cells and Ki67-positive cells in the olfactory epithelia after injection 
of CYP. In all three histological regions of the murine olfactory system that 
retained labeled co-localizations (MOE sensory zone, VNO sensory zone, and 
VNO marginal zones), administration of CYP precipitated an eventual increase 
in the number of co-localizations (figures 6, 10, 12, 16-17). This is a novel and 
intriguing result. Conventional knowledge of regeneration in the olfactory 
epithelia suggests that under normal physiological conditions, populations of 
HBCs are mostly quiescent and exist primarily to replenish populations of 
GBCs, which are thought to be the source of proliferative cells that support the 
nonstop turnover of sensory neurons (Holbrook et al., 1995; Huard & Schwob, 
1995; Carter et al., 2004; Leung et al., 2007). Our results suggest that the 
elevated number of co-localizations of Keratin 5-positive cells and Ki67-
positive cells in CYP-injured animals is evidence of HBCs directly giving rise to 
proliferative cells. This finding is rational since GBCs undergoing mitosis 
would have been arrested by the administration of CYP. Therefore, in our 
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study, we contend that HBCs in the MOE and VNO likely replenished 
populations of GBCs (as they do under normal physiological conditions), and 
also replaced populations of proliferative cells that were injured by CYP. In this 
case, it appears that pharmacologic injury amplified the proliferation workload 
for the populations of HBCs. If true, this mechanism of regeneration following 
pharmacologic injury would be distinctive from the mechanism of proliferation 
thought to exist during the physiological turnover of sensory neurons. Indeed, 
previous research has demonstrated that chemical ablation of the olfactory 
epithelia, by compounds such as zinc sulfate, methyl bromide, and 
methimazole, results in the rapid proliferation of basal cells (Schwob et al., 
1995; Williams et al., 2004; Iwai et al., 2008; Xie et al., 2010; Jang et al., 2014; 
Suzuki et al., 2015). Moreover, recent studies by Brann and colleagues have 
reported that HBCs in methimazole-injured animals exhibit a direct conversion 
to proliferative cells (2015). However, to our knowledge, our study is the first 
to demonstrate with immunohistochemical evidence that HBCs may directly 
give rise to proliferative cells after injury with a cytotoxic chemotherapeutic. 
Furthermore, our study is one of the first to affirm that HBCs have an active 
role in proliferation in the VNO, a notion that had previously been disputed 
(Joiner et al., 2015). 
It should be noted that the same discrepancy between the MOE and 
VNO observed at day 45 post injection in the number of Ki67-positive cells was 
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also observed in the number of co-localizations. At day 45 post injection, the 
number of co-localizations in the VNO of CYP-injected mice remained 
significantly elevated compared to saline-injected mice, whereas the number in 
the MOE returned to levels comparable to saline-injected mice. Again, we 
presume that this discrepancy is likely due to asynchronous cycles of 
neurogenesis in the MOE and VNO. It is likely that our results are a snapshot 
of these asynchronous cycles once our animals began to recover from the initial 
insult of CYP. We suspect that lengthened time-courses of the number of Ki67-
positive cells and the number of co-localizations will reveal divergent rates of 
proliferation in the MOE and VNO as animals recover from a cytotoxic insult. 
Overall, our results suggest that a single intraperitoneal injection of CYP 
will significantly increase the number of co-localizations of Keratin 5-positive 
cells and Ki67-positive cells in the MOE and VNO following a period of CYP-
induced injury. In the olfactory epithelia of young mice like those we tested, we 
suggest that an increase in the number of co-localizations should be viewed by 
14 days after injection of CYP, though the rates of co-localization may differ 
across time between the MOE and the VNO. 
2.4.3. Future Research Directions and Potential Clinical Impacts 
 Our study is the first to demonstrate that a cytotoxic chemotherapeutic 
can dampen proliferation in the murine olfactory system, and instigate a 
subsequent period of neurogenic recovery. Future research on olfactory 
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alterations induced by CYP can be expanded in several ways. Studies should 
utilize a large population of mice with testing occurring at several different 
stages of life (i.e. early adulthood, late adulthood, etc.). They may also include a 
variety of injections (i.e. larger doses of CYP, multiple injections of CYP, etc.) 
and several more time-points post injection to elucidate the potency of CYP 
and the efficacy of CYP in the olfactory epithelia across time. To reduce stress 
responses provoked by injection procedures, mice should be acclimated to 
tactile interactions prior to experimentation. Additionally, use of a verified 
immunohistochemical marker for the GBCs would improve our understanding 
of the interactions between HBCs and proliferative cells after injury with CYP. 
Lastly, future research should consider examining the effects of cytoprotectants 
in the murine olfactory system. In yet another innovative study, Mukherjee and 
Delay showed that pre-treatment with the cytoprotective agent amifostine 
prevented CYP-induced inhibition of cell proliferation and also protected 
against loss of mature gustatory cells after CYP exposure (2013). Since our data 
in the olfactory system mirrored trends reported by Mukherjee & Delay in the 
gustatory system, it would be reasonable to hypothesize that amifostine may 
have a cytoprotective effect on proliferative cells in the olfactory epithelia. 
Additional research on the histological effects that CYP confers on the olfactory 
system will substantially improve our understanding of how cytotoxic 
chemotherapeutics achieve chemosensory alterations. 
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 Finally, we suggest that our results may have several clinical 
implications. To our knowledge, our study is the first of its kind to explicate the 
histological underpinnings of olfactory distortion induced by administration of 
a cytotoxic chemotherapeutic. For the first time, clinicians will now have 
histological evidence to refer to in understanding how CYP may negatively 
alter their patients’ sense of smell. Moreover, our results may prompt 
newfound clinical applications for the use of CYP. Our data suggest that 
administration of CYP will elevate the number of co-localizations between 
quiescent basal cells and proliferative cells, signifying that pharmacologic 
injury can augment proliferation in the olfactory epithelia. In patients who 
have naturally-occurring hyposmia or anosmia, administration of CYP may be 
one way to intensify neurogenesis in the olfactory epithelia and rectify the 
patients’ loss of smell. This theoretical application could be especially pertinent 
for elderly adults, whose natural sense of smell wanes with aging. Future 
research will be imperative for reducing off-target side effects of CYP in the 
olfactory epithelia (such as pre-treatment with amifostine), and also for 
indicating new uses of CYP (such as intensifying neurogenesis in naturally-
occurring olfactory pathologies). 
 In conclusion, our study demonstrates that the nonspecific cytotoxic 
properties of CYP affect proliferative cells in the murine olfactory system, and 
that quiescent basal cells may have a novel role in injury-induced neurogenesis, 
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distinct from normal physiological conditions. We hope that our study will 
serve as a conduit between basic research and clinical outcomes in the fight 
against cancer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
70 
2.5. References 
Aronovitch M, Meakins JF, Groszman M (1960), Use of cyclophosphamide in 
 advanced malignancies. Can Med Assoc J 83:997-1002. 
Bagley CM, Bostick FW, DeVita VT (1973), Clinical pharmacology of 
 cyclophosphamide. Cancer Res 33:226-233. 
Barber PC, Raisman G (1978), Cell division in the vomeronasal organ of the 
 adult mouse. Brain Res. 141:57–66. 
Beites CL, Kawauchi S, Crocker CE, Calof AL (2005), Identification and 
 molecular regulation of neural stem cells in the olfactory epithelium.  
Exp Cell Res 306:309-316. 
Bernhardson BM, Tishelman C, Rutqvist LE (2007), Chemosensory changes 
 experienced by patients undergoing cancer chemotherapy: a qualitative  
interview study. J Pain Symptom Manage 34:403-412. 
Bernhardson BM, Tishelman C, Rutqvist LE (2009), Olfactory changes among 
 patients receiving chemotherapy. Eur J Oncol Nurs 13:9-15. 
Brann JH, Ellis DP, Ku BS, Spinazzi EF, Firestein S (2015), Injury in aged animals 
 robustly activates quiescent olfactory neural stem cells. Front Neurosci  
9:1-13. 
Brann JH, Firestein S (2014), A lifetime of neurogenesis in the olfactory system. 
 Front Neurosci 8:1-11. 
Brann JH, Firestein S (2010), Regeneration of new neurons is preserved in aged 
 vomeronasal epithelia. J Neurosci 30:15686-15694 
Caggiano M, Kauer JS, Hunter DD (1994), Globose basal cells are neuronal 
 progenitors in the olfactory epithelium: a lineage analysis using a 
 replication-incompetent retrovirus. Neu 13:339-352. 
Calof AL, Chikaraishi DM (1989), Analysis of neurogenesis in a mammalian 
 neuroepithelium: proliferation and differentiation of an olfactory 
 neuron precursor in vitro. Neu 3:115-127. 
Carter LA, MacDonald JL, Roskams AJ (2004), Olfactory horizontal basal cells 
 demonstrate a conserved multipotent progenitor phenotype. J Neurosci  
24:5670-5683. 
Colvin OM (1999), An overview of cyclophosphamide development and clinical  
 applications. Curr Pharm Des 5:555-560. 
Comeau TB, Epstein JB, Migas C (2001), Taste and smell dysfunction in patients 
 receiving chemotherapy: a review of current knowledge. Supp Car Can 
 9:575-580. 
Costanzo RM (1991), Regeneration of olfactory receptor cells. Ciba Found Symp 
 160:233-242. 
Cunningham D, Cummings J, Blackie RB, McTaggart L, Banham SW, Kaye SB, 
 Soukop M (1988), The pharmacokinetics of high dose cyclophosphamide 
 and high dose etoposide. Med Oncol Tumor Pharmacother 5:117-123. 
  
71 
Dick DAL, Phillips AF (1961), Clinical experience with cyclophosphamide in 
 malignant disease. Can Med Assoc J 85:974-986. 
Farbman AI (1997), Injury-stimulated neurogenesis in sensory systems. Adv 
 Neurol 72:157-61. 
Firestein S (2001), How the olfactory system makes sense of scents. Nat 413:211- 
 218. 
Foye LV, Chapman CG, Willett FM, Adams WS (1960), Cyclophosphamide. A 
 preliminary study of a new alkylating agent. Arch Intern Med 106:365- 
367 
Graziadei PPC, Monti-Graziadei GA (1979), Neurogenesis and neuron 
 regeneration in the olfactory system of mammals. I. Morphological  
aspects of differentiation and structural organization of olfactory sensory  
neurons. J. Neurocyto 8:1-18. 
Goldstein BJ, Schwob JE (1996), Analysis of the globose basal cell compartment in  
rat olfactory epithelium using GBC-1, a new monoclonal antibody 
against globose basal cells. J Neurosci 16:4005-4016. 
Halyard MY (2009), Taste and smell alterations in cancer patients – real problems  
 with few solutions. J Support Oncol 7:68-69. 
Holbrook EH, Szumowski M, Schwob JE (1995), An immunochemical, 
 ultrastructural and developmental characterization of the horizontal 
 basal cells of the rat olfactory epithelium. J Comp Neurol 363:129-146. 
Holbrook EH, Wu E, Curry WT, Lin DT, Schwob JE (2011), 
 Immunohistochemical characterization of human olfactory tissue. Laryn 
 121:1687-1701. 
Huard JMT, Schwob JE (1995), Cell cycle of globose basal cells in rat olfactory 
 epithelium. Dev Dyn 203:17-26. 
Huard JMT, Youngentob SL, Goldstein BJ, Luskin MB, Schwob JE (1998), Adult 
 olfactory epithelium contains multipotent progenitors that give rise to 
 neurons and non-neural cells. J Comp Neurol 400:469-486. 
Hutton JL, Baracos VE, Wismer WV (2007), Chemosensory dysfunction is a 
 primary factor in the evolution of declining nutritional status and  
quality of life in patients with advanced cancer. J Pain Symptom Manage  
33:156-165. 
Iwai N, Zhou Z, Roop DR, Behringer RR (2008), Horizontal basal cells are 
 multipotent progenitors in normal and injured adult olfactory  
epithelium. Stem Cells 26:1298-1306. 
Jang W, Chen X, Flis D, Harris M, Schwob JE (2014), Label-Retaining, Quiescent 
 globose basal cells are found in the olfactory epithelium. J Comp Neurol 
 522:731-749. 
Joiner AM, Green WW, McIntyre JC, Allen BL, Schwob JE, Martens JR (2015) 
 Primary cilia on horizontal basal cells regulate regeneration of the  
 olfactory epithelium. J Neurosci 35:13761-13772. 
  
72 
Juma FD, Rogers HJ, Trounce JR (1979), Pharmacokinetics of cyclophosphamide  
and alkylating activity in man after intravenous and oral administration. 
Br J Clinical Pharmacol 8:455-458. 
Juma FD, Rogers HJ, Trounce JR (1980), The pharmacokinetics of  
 cyclophosphamide, phosphoramide mustard and nor-nitrogen mustard 
 studied by gas chromatography in patients receiving cyclophosphamide 
 therapy. Br J Clin Pharmacol 10:327-335. 
Legrier ME, Ducray A, Propper A, Chao M, Kastner A (2001), Cell cycle  
 regulation during mouse olfactory neurogenesis. Cell Growth Differ  
 12:591-601. 
Leung CT, Coulombe PA, Reed RR (2007), Contribution of olfactory neural stem 
 cells to tissue maintenance and regeneration. Nat Neurosci. 10:720-726. 
Ludeman SM (1999), The chemistry of the metabolites of cyclophosphamide.  
 Curr Pharm Des 5:627-643. 
Malet-Martino M, Gilard V, Martino R (1999), The analysis of cyclophosphamide 
 and its metabolites. Curr Pharm Des 5:561-586. 
Martinez-Marcos A, Jia C, Quan W, Halpern M (2004), Neurogenesis, migration, 
 and apoptosis in the vomeronasal epithelium of adult mice. Wiley 
 Interscience 173-187. 
Meijer MK, Spruijt BM, van Zutphen LF, Baumans V (2006), Effect of restraint 
 and injection methods on heart rate and body temperature in mice. Lab 
 Anim 40:382-391. 
Mombaerts, P (2006) Axonal wiring in the mouse olfactory system. Ann Rev Cell 
 Dev Biol 22:713-727. 
Moore MJ (1991), Clinical pharmacokinetics of cyclophosphamide. Clin 
 Pharmacokinet 20:194-208. 
Morton DB, Jennings M, Buckwell A (2001), Refining Procedures for the 
 administration of substances. Lab Anim 35:1-41. 
Mukherjee N, Delay ER (2011), Cyclophosphamide-induced disruption of umami 
 taste functions and taste epithelium. Neurosci 192:732-745. 
Mukherjee N, Carroll BL, Spees JL, Delay ER (2013), Pre-Treatment with 
 amifostine protects against cyclophosphamide-induced disruption of  
taste in mice. PLoS One 1-13. 
Naessen R (1970), The identification and topographical localization of the 
olfactory epithelium in man and other animals. Acta Otolaryngol 70:51-
57. 
Pinto N, Ludeman SM, Dolan ME (2009), Drug focus: Pharmacogenetic studies  
 related to cyclophosphamide-based therapy. Pharmacogen 10:1897-1903. 
Ryba NJ, Tirindelli R (1997). A new multigene family of putative pheromone 
 receptors. Neur 19:371-379. 
Schwartz Levey M, Chikaraishi DM, Kauer JS (1991), Characterization of 
 potential precursor populations in the mouse olfactory epithelium using  
  
73 
 immunocytochemistry and autoradiography. J. Neurosci 11:3556-3564. 
Schwob JE (2002), Neuronal regeneration and the peripheral olfactory system. 
 Anat Rec 269:33-49. 
Schwob JE, Youngentob SL, Mezza RC (1995), Reconstitution of the rat olfactory 
epithelium after methyl bromide-induced lesion. J Comp Neurol 359:15-
37. 
Suzuki J, Sakurai K, Yamazaki M, Abe M, Inada H, Sakimura K, Katori Y, Osumi  
N (2015), Horizontal basal cell-specific deletion of Pax6 impedes 
recovery of the olfactory neuroepithelium following severe injury. Stem 
Cells and Development 00:1-10. 
Tucker ES, Lehtinen MK, Maynard T, Zirlinger M, Dulac C, Rawsopn N, Pevny 
 L, Lamantia AS (2010), Proliferative and transcriptional  
identity of distinct classes of neural precursors in the mammalian  
olfactory epithelium. Dev 137:2471-2481. 
Vedin V, Molander M, Bohm S, Berghard A (2009), Regional differences in 
 olfactory epithelial homeostasis in the adult mouse. J Comp Neurol  
 513:375-384. 
Weiler E (2005), Postnatal development of the rat vomeronasal organ. Chem  
 Senses 30:127-128. 
Weiler E, Benali A (2005), Olfactory epithelia differentially express neuronal  
 markers. J Neurocyt 34:217-240. 
Weiler E, Farbman AI (1998), Proliferation decrease in the olfactory epithelium  
 during postnatal development. Ann N Y Acd Sci 855:230-243. 
Weiler E, Farbman AI (1997), Proliferation in the rat olfactory epithelium: 
age-dependent changes. J. Neurosci 17:3610–3622. 
Williams SK, Gilbey T, Barnett SC (2004), Immunohistochemical studies of the 
 cellular changes in the peripheral olfactory system after zinc sulfate 
 nasal irrigation. Neurochemical Research 29:891-901. 
Xie F, Fang C, Schnittke N, Schwob J, Ding, X (2013), Mechanisms of permanent 
 loss of olfactory receptor neurons induced by the herbicide 2,6- 
dichlorobenzonitrile: effects on stem cells and noninvolvement of acute  
induction of the inflammatory cytokine IL-6. Toxicol Appl Pharmacol  
272:598-607. 
 
  
  
74 
COMPREHENSIVE BIBLIOGRPAHY 
 
 
Aronovitch M, Meakins JF, Groszman M (1960), Use of cyclophosphamide in 
 advanced malignancies. Can Med Assoc J 83:997-1002. 
 
 
Bagley CM, Bostick FW, DeVita VT (1973), Clinical pharmacology of 
 cyclophosphamide. Cancer Res 33:226-233. 
 
 
Barber PC, Raisman G (1978), Cell division in the vomeronasal organ of the 
 adult mouse. Brain Res. 141:57–66. 
 
 
Beites CL, Kawauchi S, Crocker CE, Calof AL (2005), Identification and 
 molecular regulation of neural stem cells in the olfactory epithelium.  
Exp Cell Res 306:309-316. 
 
 
Bernhardson BM, Tishelman C, Rutqvist LE (2007), Chemosensory changes 
 experienced by patients undergoing cancer chemotherapy: a qualitative  
interview study. J Pain Symptom Manage 34:403-412. 
 
 
Bernhardson BM, Tishelman C, Rutqvist LE (2009), Olfactory changes among 
 patients receiving chemotherapy. Eur J Oncol Nurs 13:9-15. 
 
 
Brann JH, Ellis DP, Ku BS, Spinazzi EF, Firestein S (2015), Injury in aged animals 
 robustly activates quiescent olfactory neural stem cells. Front Neurosci  
9:1-13. 
 
 
Brann JH, Firestein S (2014), A lifetime of neurogenesis in the olfactory system. 
 Front Neurosci 8:1-11. 
 
 
Brann JH, Firestein S (2010), Regeneration of new neurons is preserved in aged 
 vomeronasal epithelia. J Neurosci 30:15686-15694 
 
 
  
75 
Caggiano M, Kauer JS, Hunter DD (1994), Globose basal cells are neuronal 
 progenitors in the olfactory epithelium: a lineage analysis using a 
 replication-incompetent retrovirus. Neu 13:339-352. 
 
 
Calof AL, Chikaraishi DM (1989), Analysis of neurogenesis in a mammalian 
 neuroepithelium: proliferation and differentiation of an olfactory 
 neuron precursor in vitro. Neu 3:115-127. 
 
 
Carter LA, MacDonald JL, Roskams AJ (2004), Olfactory horizontal basal cells 
 demonstrate a conserved multipotent progenitor phenotype. J Neurosci  
24:5670-5683. 
 
 
Colvin OM (1999), An overview of cyclophosphamide development and clinical  
 applications. Curr Pharm Des 5:555-560. 
 
 
Comeau TB, Epstein JB, Migas C (2001), Taste and smell dysfunction in patients 
 receiving chemotherapy: a review of current knowledge. Supp Car Can 
 9:575-580. 
 
 
Costanzo RM (1991), Regeneration of olfactory receptor cells. Ciba Found Symp 
 160:233-242. 
 
 
Cunningham D, Cummings J, Blackie RB, McTaggart L, Banham SW, Kaye SB, 
 Soukop M (1988), The pharmacokinetics of high dose cyclophosphamide 
 and high dose etoposide. Med Oncol Tumor Pharmacother 5:117-123. 
 
 
Dias BG, Ressler KJ (2014), Parental olfactory experience influences behavior and  
 neural structure in subsequent generations. Nat Neurosci. 17:89-96. 
 
 
Dick DAL, Phillips AF (1961), Clinical experience with cyclophosphamide in 
 malignant disease. Can Med Assoc J 85:974-986. 
 
 
 
  
76 
Farbman AI (1997), Injury-stimulated neurogenesis in sensory systems. Adv 
 Neurol 72:157-61. 
 
 
Firestein S (2001), How the olfactory system makes sense of scents. Nat 413:211- 
 218. 
 
 
Foye LV, Chapman CG, Willett FM, Adams WS (1960), Cyclophosphamide. A 
 preliminary study of a new alkylating agent. Arch Intern Med 106:365- 
367 
 
 
Gokoffski KK, Kawauchi S, Wu HH, Santos R, Hollenbeck PLW, Lander AD, 
 Calof AL (2010), Feedback regulation of neurogenesis in the mammalian  
olfactory epithelium: new insights from genetics and systems biology. In:  
The neurobiology of olfaction (Menini A, ed), pp 241-266. 
 
 
Graziadei PPC, Monti-Graziadei GA (1979), Neurogenesis and neuron 
 regeneration in the olfactory system of mammals. I. Morphological  
aspects of differentiation and structural organization of olfactory sensory  
neurons. J. Neurocyto 8:1-18. 
 
 
Goldstein BJ, Schwob JE (1996), Analysis of the globose basal cell compartment in  
rat olfactory epithelium using GBC-1, a new monoclonal antibody 
against globose basal cells. J Neurosci 16:4005-4016. 
 
 
Halyard MY (2009), Taste and smell alterations in cancer patients – real problems  
 with few solutions. J Support Oncol 7:68-69. 
 
 
Holbrook EH, Szumowski M, Schwob JE (1995), An immunochemical, 
 ultrastructural and developmental characterization of the horizontal 
 basal cells of the rat olfactory epithelium. J Comp Neurol 363:129-146. 
 
 
Holbrook EH, Wu E, Curry WT, Lin DT, Schwob JE (2011), 
 Immunohistochemical characterization of human olfactory tissue. Laryn 
 121:1687-1701. 
  
77 
Huard JMT, Schwob JE (1995), Cell cycle of globose basal cells in rat olfactory 
 epithelium. Dev Dyn 203:17-26. 
 
 
Huard JMT, Youngentob SL, Goldstein BJ, Luskin MB, Schwob JE (1998), Adult 
 olfactory epithelium contains multipotent progenitors that give rise to 
 neurons and non-neural cells. J Comp Neurol 400:469-486. 
 
 
Hutton JL, Baracos VE, Wismer WV (2007), Chemosensory dysfunction is a 
 primary factor in the evolution of declining nutritional status and  
quality of life in patients with advanced cancer. J Pain Symptom Manage  
33:156-165. 
 
 
Iwai N, Zhou Z, Roop DR, Behringer RR (2008), Horizontal basal cells are 
 multipotent progenitors in normal and injured adult olfactory  
epithelium. Stem Cells 26:1298-1306. 
 
 
Jang W, Chen X, Flis D, Harris M, Schwob JE (2014), Label-Retaining, Quiescent 
 globose basal cells are found in the olfactory epithelium. J Comp Neurol 
 522:731-749. 
 
 
Joiner AM, Green WW, McIntyre JC, Allen BL, Schwob JE, Martens JR (2015) 
 Primary cilia on horizontal basal cells regulate regeneration of the  
 olfactory epithelium. J Neurosci 35:13761-13772. 
 
 
Juma FD, Rogers HJ, Trounce JR (1979), Pharmacokinetics of cyclophosphamide  
and alkylating activity in man after intravenous and oral administration. 
Br J Clinical Pharmacol 8:455-458. 
 
 
Juma FD, Rogers HJ, Trounce JR (1980), The pharmacokinetics of  
 cyclophosphamide, phosphoramide mustard and nor-nitrogen mustard 
 studied by gas chromatography in patients receiving cyclophosphamide 
 therapy. Br J Clin Pharmacol 10:327-335. 
 
 
 
  
78 
Krolewski RC, Packard A, Schwob JE (2013), Global expression profiling of 
 globose basal cells and neurogenic progression within the olfactory 
 epithelium. J Comp Neurol 521:1-26. 
 
 
Legrier ME, Ducray A, Propper A, Chao M, Kastner A (2001), Cell cycle  
 regulation during mouse olfactory neurogenesis. Cell Growth Differ  
 12:591-601. 
 
 
Leung CT, Coulombe PA, Reed RR (2007), Contribution of olfactory neural stem 
 cells to tissue maintenance and regeneration. Nat Neurosci. 10:720-726. 
 
 
Ludeman SM (1999), The chemistry of the metabolites of cyclophosphamide.  
 Curr Pharm Des 5:627-643. 
 
 
Malet-Martino M, Gilard V, Martino R (1999), The analysis of cyclophosphamide 
 and its metabolites. Curr Pharm Des 5:561-586. 
 
 
Martinez-Marcos A, Jia C, Quan W, Halpern M (2004), Neurogenesis, migration, 
 and apoptosis in the vomeronasal epithelium of adult mice. Wiley 
 Interscience 173-187. 
 
 
Matsunami H, Buck LB (1997), A multigene family encoding a diverse array of 
 putative pheromone receptors in animals. Cell 90:775-784. 
 
 
Meijer MK, Spruijt BM, van Zutphen LF, Baumans V (2006), Effect of restraint 
 and injection methods on heart rate and body temperature in mice. Lab 
 Anim 40:382-391. 
 
 
Mombaerts, P (2006) Axonal wiring in the mouse olfactory system. Ann Rev Cell 
 Dev Biol 22:713-727. 
 
 
Moore MJ (1991), Clinical pharmacokinetics of cyclophosphamide. Clin 
 Pharmacokinet 20:194-208. 
  
79 
Morton DB, Jennings M, Buckwell A (2001), Refining Procedures for the 
 administration of substances. Lab Anim 35:1-41. 
 
 
Mukherjee N, Delay ER (2011), Cyclophosphamide-induced disruption of umami 
 taste functions and taste epithelium. Neurosci 192:732-745. 
 
 
Mukherjee N, Carroll BL, Spees JL, Delay ER (2013), Pre-Treatment with 
 amifostine protects against cyclophosphamide-induced disruption of  
taste in mice. PLoS One 1-13. 
 
 
Mumm JS, Shou J, Calof AL (1996), Colony-forming progenitors from 
 mouse olfactory epithelium: evidence for feedback regulation of neuron 
 production. Proc Natl Acad Sci USA 93:11167-11172. 
 
 
Murdoch B, Roskams AJ (2007), Olfactory epithelium progenitors: insights from 
 transgenic mice and in vitro biology. J Mol Histol 38:581-599. 
 
 
Naessen R (1970), The identification and topographical localization of the 
olfactory epithelium in man and other animals. Acta Otolaryngol 70:51-
57. 
 
 
Pinto N, Ludeman SM, Dolan ME (2009), Drug focus: Pharmacogenetic studies  
 related to cyclophosphamide-based therapy. Pharmacogen 10:1897-1903. 
 
 
Ryba NJ, Tirindelli R (1997). A new multigene family of putative pheromone 
 receptors. Neur 19:371-379. 
 
 
Schwartz Levey M, Chikaraishi DM, Kauer JS (1991), Characterization of 
 potential precursor populations in the mouse olfactory epithelium using  
 immunocytochemistry and autoradiography. J. Neurosci 11:3556-3564. 
 
 
Schwob JE (2002), Neuronal regeneration and the peripheral olfactory system. 
 Anat Rec 269:33-49. 
  
80 
Schwob JE, Youngentob SL, Mezza RC (1995), Reconstitution of the rat olfactory 
epithelium after methyl bromide-induced lesion. J Comp Neurol 359:15-
37. 
 
 
Suzuki J, Sakurai K, Yamazaki M, Abe M, Inada H, Sakimura K, Katori Y, Osumi  
N (2015), Horizontal basal cell-specific deletion of Pax6 impedes 
recovery of the olfactory neuroepithelium following severe injury. Stem 
Cells and Development 00:1-10. 
 
 
Tucker ES, Lehtinen MK, Maynard T, Zirlinger M, Dulac C, Rawsopn N, Pevny 
 L, Lamantia AS (2010), Proliferative and transcriptional  
identity of distinct classes of neural precursors in the mammalian  
olfactory epithelium. Dev 137:2471-2481. 
 
 
Vedin V, Molander M, Bohm S, Berghard A (2009), Regional differences in 
 olfactory epithelial homeostasis in the adult mouse. J Comp Neurol  
 513:375-384. 
 
 
Weiler E (2005), Postnatal development of the rat vomeronasal organ. Chem  
 Senses 30:127-128. 
 
 
Weiler E, Benali A (2005), Olfactory epithelia differentially express neuronal  
 markers. J Neurocyt 34:217-240. 
 
 
Weiler E, Farbman AI (1998), Proliferation decrease in the olfactory epithelium  
 during postnatal development. Ann N Y Acd Sci 855:230-243. 
 
 
Weiler E, Farbman AI (1997), Proliferation in the rat olfactory epithelium: 
age-dependent changes. J. Neurosci 17:3610–3622. 
 
 
Williams SK, Gilbey T, Barnett SC (2004), Immunohistochemical studies of the 
 cellular changes in the peripheral olfactory system after zinc sulfate 
 nasal irrigation. Neurochemical Research 29:891-901. 
 
  
81 
Xie F, Fang C, Schnittke N, Schwob J, Ding, X (2013), Mechanisms of permanent 
 loss of olfactory receptor neurons induced by the herbicide 2,6- 
dichlorobenzonitrile: effects on stem cells and noninvolvement of acute  
induction of the inflammatory cytokine IL-6. Toxicol Appl Pharmacol  
272:598-607. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
82 
APPENDIX 
Table 1: Levene’s Test for Equality of Variances and Two-Sample t-Test for Equality of 
Means for the Number of Ki67-Positive Cells and the Number of Co-Localizations of 
Keratin 5-Positive  and Ki67-Positive Cells in the Murine Main Olfactory Epithelium of 
CYP-Injected Mice and Saline-Injected Mice over 45 Days Post Injection. Levene’s test and a 
two-sample t-test were performed to analyze the differences in number of Ki67-positive cells 
and the number of co-localizations of Keratin 5-positive and Ki67-positive cells in the Main 
Olfactory Epithelium (MOE) of CYP-injected and saline-injected mice one, two, six, 14, 30, and 
45 days post injection. Levene’s test was performed to determine if the number of Ki67-positive 
cells and the number of co-localizations of Keratin 5-positive and Ki67-positive cells in the 
MOE of CYP-injected mice and saline-injected mice retained equal variances at days one, two, 
six, 14, 30 and 45 post injection. A two-sample t-test was performed to determine if the mean 
number of Ki67-positive cells and the mean number of co-localizations of Keratin 5-positive 
and Ki67-positive cells in the MOE of CYP-injected and saline-injected mice were equal at days 
one, two, six, 14, 30 and 45 post injection. The alpha level for both tests was 0.050. If the 
reported p-value of a test was less than the alpha level, the result was recognized as statistically 
significant. 
 
Levene’s 
Test 
Two Sample t-Test 
  F Sig.  t df Sig.  Mean 
Difference 
DAY 1  
Post Injection 
MOE Sensory Zone: 
Number of Ki67-Positive Cells 
0.17 0.68 2.17 41 0.02* 3.5868 
 MOE Sustentacular Zone: 
Number of Ki67-Positive Cells 
0.31 0.58 0.85 41 0.38 0.5155 
 MOE Sensory Zone: 
Number of Co-Localized Cells 
0.04 0.84 -0.50 41 0.62 -.8534 
DAY 2  
Post Injection 
MOE Sensory Zone: 
Number of Ki67-Positive Cells 
0.31 0.59 -5.18 37 0.00* 1.3714 
 MOE Sustentacular Zone: 1.22 0.29 -1.48 37 0.15 0.9002 
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Number of Ki67-Positive Cells 
DAY 6  
Post Injection 
MOE Sensory Zone: 
Number of Ki67-Positive Cells 
0.00 0.98 -1.27 24 0.22 -3.0931 
 MOE Sustentacular Zone: 
Number of Ki67-Positive Cells 
0.01 0.90 -2.64 24 0.01* -2.3904 
 MOE Sensory Zone: 
Number of Co-Localized Cells 
0.33 0.57 -3.51 24 0.00* -3.0595 
DAY 14  
Post Injection 
MOE Sensory Zone: 
Number of Ki67-Positive Cells 
0.31 0.58 2.31 24 0.02* 3.8161 
 MOE Sustentacular Zone: 
Number of Ki67-Positive Cells 
4.17 0.06 0.85 24 0.33 1.0113 
 MOE Sensory Zone: 
Number of Co-Localized Cells 
7.66 0.01 2.35 24 0.03* 4.7858 
DAY 30  
Post Injection 
MOE Sensory Zone: 
Number of Ki67-Positive Cells 
0.17 0.68 2.89 20 0.00* 1.9716 
 MOE Sustentacular Zone: 
Number of Ki67-Positive Cells 
0.00 0.93 2.13 20 0.04* 0.6373 
 MOE Sensory Zone: 
Number of Co-Localized Cells 
0.61 0.44 3.39 20 0.00* 1.0636 
DAY 45  
Post Injection 
MOE Sensory Zone: 
Number of Ki67-Positive Cells 
2.61 0.11 0.08 25 0.92 0.0839 
 MOE Sustentacular Zone: 
Number of Ki67-Positive Cells 
0.09 0.75 0.24 25 0.80 0.0946 
 MOE Sensory Zone: 
Number of Co-Localized Cells 
1.57 0.23 1.16 25 0.24 0.9419 
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Table 2: Levene’s Test for Equality of Variances and Two-Sample t-Test for Equality of 
Means for the Number of Ki67-Positive Cells and the Number of Co-Localizations of 
Keratin 5-Positive  and Ki67-Positive Cells in the Murine Vomeronasal Organ of CYP-
Injected Mice and Saline-Injected Mice over 45 Days Post Injection.  
Levene’s test and a two-sample t-test were performed to analyze the differences in number of 
Ki67-positive cells and the number of co-localizations of Keratin 5-positive and Ki67-positive 
cells in the Vomeronasal Organ (VNO) of CYP-injected and saline-injected mice one, two, six, 
14, 30, and 45 days post injection. Levene’s test was performed to determine if the number of 
Ki67-positive cells and the number of co-localizations of Keratin 5-positive and Ki67-positive 
cells in the VNO of CYP-injected mice and saline-injected mice retained equal variances at days 
one, two, six, 14, 30 and 45 post injection. A two-sample t-test was performed to determine if 
the mean number of Ki67-positive cells and the mean number of co-localizations of Keratin 5-
positive and Ki67-positive cells in the VNO of CYP-injected and saline-injected mice were equal 
at days one, two, six, 14, 30 and 45 post injection. The alpha level for both tests was 0.050. If the 
reported p-value of a test was less than the alpha level, the result was recognized as statistically 
significant. 
 
Levene’s 
Test 
Two Sample t-Test 
  F Sig.  t df Sig.  Mean 
Difference 
DAY 1  
Post Injection 
VNO Sensory Zone: 
Number of Ki67-Positive Cells 
0.31 0.59 -2.14 14 0.05* -0.6662 
 VNO Sustentacular Zone: 
Number of Ki67-Positive Cells 
0.20 0.66 -1.66 14 0.04 -1.3490 
 VNO Marginal Zones: 
Number of Ki67-Positive Cells 
2.88 0.11 -0.34 14 0.73 -0.7553 
 VNO Sensory Zone: 
Number of Co-Localized Cells 
2.46 0.13 -1.33 14 0.20 -0.1114 
 VNO Marginal Zones: 
Number of Co-Localized Cells 
0.66 0.43 -1.73 14 0.01* -1.4225 
DAY 2  VNO Sensory Zone: 0.05 0.82 -4.37 17 0.00* -1.0580 
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Post Injection Number of Ki67-Positive Cells 
 VNO Sustentacular Zone: 
Number of Ki67-Positive Cells 
19.1 0.00 -2.90 17 0.01* -3.4117 
 VNO Marginal Zones: 
Number of Ki67-Positive Cells 
0.26 0.61 -1.80 17 0.04* -2.9409 
DAY 6  
Post Injection 
VNO Sensory Zone: 
Number of Ki67-Positive Cells 
1.85 0.19 -2.13 16 0.04* -0.5993 
 VNO Sustentacular Zone: 
Number of Ki67-Positive Cells 
0.02 0.89 -3.04 16 0.00* -1.0427 
 VNO Marginal Zones: 
Number of Ki67-Positive Cells 
0.41 0.53 -0.41 16 0.68 -0.3012 
 VNO Sensory Zone: 
Number of Co-Localized Cells 
0.14 0.71 0.13 16 0.89 0.0144 
 VNO Marginal Zones: 
Number of Co-Localized Cells 
2.11 0.17 -1.45 16 0.17 -1.0077 
DAY 14  
Post Injection 
VNO Sensory Zone: 
Number of Ki67-Positive Cells 
0.38 0.55 -0.12 22 0.90 0.0356 
 VNO Sustentacular Zone: 
Number of Ki67-Positive Cells 
0.05 0.83 -0.50 22 0.58 -0.3891 
 VNO Marginal Zones: 
Number of Ki67-Positive Cells 
15.1 0.00 3.16 22 0.01* 5.2782 
 VNO Sensory Zone: 
Number of Co-Localized Cells 
1.60 0.22 0.39 22 0.70 0.0608 
 VNO Marginal Zones: 
Number of Co-Localized Cells 
5.79 0.03 1.00 22 0.33 0.7318 
DAY 30  
Post Injection 
VNO Sensory Zone: 
Number of Ki67-Positive Cells 
10.1 0.00 2.99 14 0.00* 1.3009 
 VNO Sustentacular Zone: 
Number of Ki67-Positive Cells 
4.71 0.04 1.47 14 0.04* 0.9865 
 VNO Marginal Zones: 
Number of Ki67-Positive Cells 
0.16 0.69 1.42 14 0.17  1.8248 
 VNO Sensory Zone: 
Number of Co-Localized Cells 
0.26 0.61 1.15 14 0.24 0.1651 
 VNO Marginal Zones: 
Number of Co-Localized Cells 
0.01 0.94 1.21 14 0.24 0.4791 
DAY 45  
Post Injection 
VNO Sensory Zone: 
Number of Ki67-Positive Cells 
6.38 0.02 1.77 16 0.03* 1.9413 
 VNO Sustentacular Zone: 
Number of Ki67-Positive Cells 
3.31 0.07 3.08 16 0.00* 4.0031 
 VNO Marginal Zones: 
Number of Ki67-Positive Cells 
0.91 0.35 1.51 16 0.03* 3.1887 
 VNO Sensory Zone: 
Number of Co-Localized Cells 
3.77 0.07 2.98 16 0.00* 0.5863 
 VNO Marginal Zones: 
Number of Co-Localized Cells 
3.38 0.08 2.30 16 0.01*  1.4235 
 
